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Platelet-Rich Plasma (PRP) and Leucocytes-PRP (L-PRP) are blood products widely used 
to promote wound healing that have also shown antimicrobial activity. The aim of the 
study was to perform a systematic review of the literature on the contribution of leucocytes 
included in PRP preparations in terms of their antimicrobial properties and to conduct in 
vitro studies to explore the antimicrobial properties of blood products against free bacteria 
and bacteria-forming biofilm. Assays included growth kinetics and crystal violet biofilm 
formation assays. 
The systematic review revealed that the limited numbers of studies so far conducted did 
not allow determination of the specific contribution of leucocytes to the bactericidal effect 
of PRP preparations. However, overall, PRP preparations do de monstrate bacteriostatic 
properties against the majority of the bacterial strains tested in the literature. From the in 
vitro studies carried out here the only preparation showing growth control of 
Staphylococcus aureus was the L-PRP preparation, where the leukocyte and neutrophil 
content of the preparation both significantly influenced bacterial growth kinetics. PRP and 
PPP (Platelet Poor Plasma) preparations significantly reduced Pseudomonas and 
Acinetobacter growth over a 12-hour period. Against the Gram-negative bacteria, all the 
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CHAPTER 1: INTRODUCTION 
 
Over the last few years, one of the hottest areas in regenerative medicine has been research 
focusing on enhancing and promoting tissue repair and regeneration [1]. Burns and chronic 
wounds represent a continuing challenge for physicians in terms of treatment, and for 
healthcare services in terms of elevated costs [2, 3]. The infection of a wound  is one of the 
major contributors to delays in wound healing and tissue regeneration [4, 5]. As multidrug 
resistance to antibiotics is becoming a serious threat [6], research in this field has focused 
on finding new agents and strategies to fight infection [7] and additionally to reduce 
healing times. Recent literature suggests that Platelet Rich-Plasma (PRP), a blood-derived 
component used in wound care as a topical biological accelerator of the healing process, 
can also exert antimicrobial activity. Leucocyte-Platelet Rich-Plasma (L-PRP) is the 
terminology used when leucocytes are included in PRP products [8]. 
This research study aims to explore the antimicrobial properties of PRP products against 
free bacteria and bacteria forming biofilms commonly found in wounds.  
1.1 Definition of PRP 
The topical use of autologous Platelet Rich-Plasma (PRP) has been safely used as a 
biological accelerator of the healing process for wounds since the 1990s [9, 10].  PRP is a 
derivative of whole blood that contains an increased concentration of platelets compared to 
the circulating blood platelet count. A working definition of PRP has been suggested as a 
concentration of cells of between  4 to 5-fold higher than the circulating blood platelet 
count [11]. PRP can be prepared in several different methods and according to the 
preparation methodology the final product obtained varies widely.  Many different 
procedures to obtain PRP have been proposed and used in clinical settings. During the 
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extraction and concentration of platelets from whole blood, leucocytes can either be 
included in the final product at different concentrations or totally excluded from the 
preparation. By most authors, platelet concentrates are generically termed as PRP.  This 
term is extremely vague and incomplete as the specific biological components are not 
considered [12, 13]. Such variations of cellular components included in PRP are often 
poorly defined in published studies making it challenging to interpret and compare the 
clinical and antimicrobial effects of various PRP preparations between different studies [8, 
14].  Recently this issue has been addressed and in an attempt to classify PRP products, 
two classifications have been suggested by Ehrenfest [15] and Mishra [16]. Ehrenfest 
suggested a classification based on the cellular components and fibrin content included in 
the blood product (Table 1.1).  
PRP Class Leucocytes Fibrin 
P-PRP No Low 
L-PRP Yes Low 
P-PRF No High 
L-PRF Yes High 
Table 1.1 Ehrenfest PRP classification system 
In the Mishra classification system PRP products are divided according to their white cell 
inclusion, method of activation and platelet concentration (Table 1.2).  
 Leucocytes Activation Platelet Concentration 
Type 1 Increased No activation A >5x 
B <5x 
Type 2 Increased Activated A >5x 
B <5x 
Type 3 Minimal or no WBC No activation A >5x 
B <5x 
Type 4 Minimal or no WBC Activation A >5x 
B <5x 
Table 1.2. Mishra PRP classification system 
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1.2 Methods of PRP preparation  
It has been shown that several factors contribute to the possible antimicrobial and healing 
efficacy of PRP products [19]. The presence and concentration of the different components 
included in PRP preparation, the methodology used to prepare the product and the 
methodology used to activate the platelets will all contribute to efficacy.  
1.2.1 Blood collection and anticoagulant choice 
To prevent activation/damage of platelets due to mechanical stress, a large bore needle is 
recommended to draw blood and usually 10% recovery of PRP is gained from a set blood 
volume. In order to prevent early platelet activation and clot formation, it is important to 
include an anticoagulant. Different anticoagulants have been suggested to be valid such as 
citrate dextrose A (ACD-A) and trisodium citrate solution [17, 18]. The use of Ethylene 
Diamine Tetra Acetic acid (EDTA) is not recommended as it has been shown to 
activate/damage a large number of platelets [12].  
1.2.2 Centrifugation  
At the International Society on Thrombosis and Haemostasis (ISTH), the platelet 
physiology subcommittee of the Scientific and Standardisation Committee (SSC) 
recommended to use a set g value for platelet preparation [19]. Using a single step low g 
centrifugation (170 – 200 g) of anticoagulated blood for 10 minutes at 21°C, a relatively 
pure preparation and reasonable harvest of PRP can be easily achieved [20]. The 
temperature recommended is 21°-24°C [12]. Several methods using different 
centrifugation speeds are available to prepare PRP have been reported but most authors 
agree a two-step centrifugation technique is best. Following a ‘soft’ spin centrifugation 
three layers become apparent: the bottom layer comprises red blood cells, the middle layer 
includes platelets and white blood cells (also referred as “buffy coat”) and the top layer 
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contains plasma and platelets. The obtained supernatant plasma is transferred into another 
tube and a second ‘high’ speed centrifugation is performed and a platelet pellet at the 
bottom of the tube is obtained. The upper layer consists of platelet-poor-plasma (PPP) and 
it is used to re-suspend the pellet to a desired final platelets concentration. After multiple 
attempts, Dhurat et al [12] described that a first  centrifugation of  900g x 5 min, followed 
by a second centrifugation of 1000g x 10 min at 16°C, gave over 1 million/ml platelets 
yield. With this method a large variability of red cell and leukocyte contamination must be 
addressed. If the collection and inclusion of leucocytes into the PRP preparation is instead 
the aim of the procedure, 2 methods to obtain L-PRP are possible. The first method is the 
single step ‘high’ spin centrifugation, with the discharge of the upper layer plasma and the 
collection of the buffy coat layer. The second method is the same as previously described 
[12]: two-steps of centrifugation, including, after the first centrifugation, the collection of 
the entire buffy coat. 
1.2.3 Activation of PRP 
PRP routinely has to be activated for the platelets to release their granule constituents for 
full expression of their potential biological activities in vivo [21]. The platelets can either 
be activated immediately either prior to or during  their application to the wound site or 
even left to be activated in situ within the damaged tissue site by naturally expressed 
platelet agonists e.g. collagen and thrombin [21]. As collagen is naturally present in human 
tissue, the activation by other means may not always be required when PRP is used 
clinically [22-24]. When PRP is activated, fibrinogen is converted to fibrin and a fibrin 
network is formed. The fibrin clot allows the capture of the released proteins, cytokines, 
growth factors and cells. This fibrin matrix can serve as a natural matrix which has also 
shown promising results in wound healing, mainly in dental applications [25]. Different 
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activators have been suggested and studied including thrombin, calcium chloride, collagen 
or mechanical trauma [12]. The safest activator seems to be calcium chloride. It has been 
shown that bovine thrombin can cause coagulopathy due to the cross-reactivity of anti-
bovine factor V antibodies and human factor V [26, 27]. The activation with calcium 
chloride has the disadvantage that it takes at least 20 minutes [10], which can be a long 
time in a clinical setting. Autologous thrombin is another safe and fast activator and lately, 
autologous thrombin preparation kits are now available [28].  
1.3 Why topical use of PRP in skin wound healing? 
 
1.3.1 Wound healing  
Skin is the largest organ in the human body, with a total area of about 2.0 square meters 
and a weight of about 6 to 10 kg in adults. Several essential functions are exerted by the 
skin including protection against infection, thermoregulation, and homeostasis [29]. Acting 
as a barrier [30], the skin provides protection from micro-organisms, photo-damage and 
chemicals, mechanical forces, and changes in temperature. The skin has also relevant 
immunological and metabolic functions. The skin is for example the major natural source 
of the vitamin D[31].  
Skin has two anatomical layers: epidermis and dermis (figures 1.1 and 1.2). 
The epidermis is the external layer of skin which is a nonvascular structure derived from 
ectoderm and it is composed of several layers of epidermal cells [30]. Different parts of the 
human body have different thickness of epidermis, being the thinnest on the eyelids 
(0.05mm) and the thickest on the palms and soles (1.5mm). The stratum basale is the inner 
part of the epidermis, composed of perpendicularly arranged columnar cells, covered by 
several layers of flattened cells. Stratum basale, spinosum, granulosum, lucidum and 
corneum comprise the overall epidermis. The skin’s colour is created by melanocytes 
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located within the stratum basale. Due to the production of pigment melanin, they are 
responsible for variations in individual skin colour.  The aim of melanogenesis is to protect 








Beneath the epidermis is the dermis which is the mesoderm derived layer. It is vascularised 
and largely made of collagen containing hair follicles, sweat, and sebaceous glands. The 
loss of epidermis, due to burns or other injuries, can be replaced by the dermal layer able to 
reproduce new epithelial cells. Finally, the hypodermis, beneath the dermis, is the layer 
subcutaneous rich fat and connective tissue. The entire epidermis is completely and 
spontaneously replaced over a period of about 48 days. 
The stratum basale constantly replaces the squamous epithelium by cell division. Cells 
undergo multiple stages of differentiation, lose their nucleus, change their shape and are 
finally shed from the surface.  Therefore, micro trauma or minor injuries affecting only the 
epidermis will heal itself restoring the damaged epidermis, whereas when injuries affect 
the dermis the body responds with a process named “wound healing”.  
 8 
The aim of wound healing is to obtain a similar if not identical tissue to the one that has 
been lost or severely damaged. A complete tissue restoration is only seen in fetal healing 
[32], whilst in children and adults, the wound healing process allows to substitute the lost 
skin with the formation of the scar tissue,  a similar tissue in function and structure, but 
never identical from its original condition. Several factors influence the outcome of tissue 
repair, and each step of the healing process is extremely relevant [33]. Any variations 
disturbing the  controlled timely healing processes would contribute with an extension of 
tissue damage,  a prolonged tissue repair and a worsening of cosmetic scar outcome [34]  
1.3.4 PRP and wound healing  
PRP has been proposed as a wound healing accelerator since the early 1990s [35]. The 
beneficial effects of PRP on the healing process and its reduction of local inflammation 
have been extensively reported in dental, orthopaedic, cardiac, gynaecologic, general 
surgery and plastic surgery fields [9, 13-15].  
Platelets promote the wound healing process through their release of a vast array of 
granule components and biological mediators, including alpha-granular growth factors 
which promote the chemotaxis of leucocytes, fibroblasts and myofibroblasts, as well the 
synthesis of extracellular matrix (ECM) and promotion of neoangiogenesis [9, 11, 12]. 
PRP is thought to restore the complex natural physiological balance required for wound 
healing, and in doing so, acts to accelerate this process [8].  
In vitro studies showed the effect of PRP preparations added to serum-free Dulbecco’s 
Modified Eagle Medium for the culture of human adipose–derived stem cells and human 
dermal fibroblasts. The effect of PRP seems to be dose dependent with a concentration of 
5% of activated PRP  stimulating the proliferation of dermal fibroblast and adipose-derived 
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stem cells, whereas a concentration of 20% did not show promotion of fibroblast 
proliferation [36]. Clinical studies in regards the beneficial effects of topical PRP in skin 
wound healing so far conducted report contrasting results [37, 38]. Positive results with 
significant enhancement of wound closure have been demonstrated with the use of PRP in 
different type of wounds [37-39]. In contrast, no benefits in terms of enhancement of 
epithelialisation were reported when PRP was used in donor sites and meshed split skin 
graft healing in chronic leg ulcers [40]. Although, in the same population, less pain was 
experienced by patients during the dressing when platelet concentrate was applied. 
Even though several systematic reviews of the use of PRP in wound healing suggest that 
the application of PRP significantly improves wound healing [9, 41, 42], in 2012 a 
Cochrane review emphasised that there was no strong evidence to recommend the use of 
PRP in chronic wounds [14]. This is due to the variability of the methods used to prepare 
PRP and the small sample size of the trials. 
In 2014, the effect of PRP specifically in treating burns wounds was summarised in a 
systematic review [43]. There is still currently a paucity of studies that explore the use of 
PRP in burns and results reported are dissimilar. When compared to silver sulfadiazine, 
burns treated with topical PRP showed an acceleration of the healing time [44]. 
Encouraging responses have been reported by the use of single growth factors (such as 
platelet-derived growth factor-BB, epidermal growth factor) in the treatment of burn wounds in 
terms of acceleration of wound healing [45, 46]. It has also been reported that the use of 
fibroblast growth factor can in the long term contribute to a better colour match when 
combined with a split skin graft [47]. Enhancement of wound healing and improvement of 
scar outcome has also been reported when fibroblast growth factor has been included in the 
treatment of second degree burns compared to placebo [48, 49]. 
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Recently Marck et al. [50] conducted a randomised, double blind, intra-patient controlled 
study using PRP in the treatment of deep dermal burns. The authors have reported that no 
significant improvement was detected in terms of graft take, epithelisation and scar quality 
when PRP was used in conjunction to skin graft compared to skin graft only. It is relevant 
to notice the considerable variation of the burn population included in the study and the 
great difference in the PRP preparation used (concentration of platelets and leucocytes). 
Moreover, PRP applied in skin graft was extracted from blood of acutely burned patients. 
It is well known that in this population platelets are massively activated due to the peculiar 
nature of the burn trauma [51]. Not surprisingly, in these patients, a great fluctuation in the 
platelet count is seen. Platelet counts in whole blood significantly decrease by day 3 post-
burn  and reach a peak at day 15 post-injury [52, 53]. As the skin graft and PRP were 
applied at different time points between patients, it is sensible to consider that the 
outcomes may be also affected by this variation.  
Additionally, the impact of PRP on long term scarring has not been adequately evaluated. 
The chemotactic effect of platelets, growth factors, and leucocytes, when included in the 
preparation, may contribute to a pro-inflammatory environment that may negatively 
influence tissue regeneration [54]. So far there are no reports of hypertrophic scarring 
related with PRP application in wounds. Moreover, the inclusion of leucocytes in a PRP 
preparation could be detrimental. The activation of platelets with the release of growth 
factors, could induce fibroblasts to proliferate [55] and increase collagen deposition [56] 
and formation of granulation tissue. TGF-β has regulatory function for the extracellular 
matrix formation and deposition. An animal study conducted in horses showed that the use 
of PRP in deep dermal burns accelerates wound repair but also induced fibrosis, which is 
 11 
not a desirable long-term outcome in terms of scarring, because of the aesthetic 
consequences [57].  
The addition of leucocytes to the wound site can also result with an increase of TGF-β1 
and TGF-β2 levels [54, 58] that have both been previously associated with higher risk of 
hypertrophic scarring and keloid formation [59-64].  
 
Overall, at present, even if strong evidence on the use of PRP in burns and wound healing 
have not been shown, negative effects of the use of PRP have also not been reported. This 
should encourage clinicians to continue to consider PRP as a strategy to treat wounds and 
to stimulate scientists to continue researches in this field.  
1.4 PRP and prevention of infection  
The infection of a wound  is one of the major contributors to the delay in wound healing 
and tissue regeneration [4, 5]. With the skin significantly disrupted or destroyed following 
a trauma affecting the skin, patients lose the body’s primary defense to infection. Plasma 
components, platelets, and leucocytes included in a PRP preparation are all potential  
contributors to the microbicidal effect of PRP documented in in vitro and in vivo studies 
[65]. Platelets can contribute to host defense through several mechanisms of action [66-
71]. Three different types of granules are found in the platelets: α, δ and λ granules. Whilst 
δ and λ granules contribute mainly to the vascular tone and to the promotion of tissue 
regeneration, the contents of α granules support to tissue regeneration with around 30 
growth factors, as well as host defense [66, 67]. Alpha granules in fact, contain various 
groups of proteins with antimicrobial properties including kinocidins and 7 platelet 
microbicidal proteins (PMPs): fibrinopeptide A and B, thymosin beta 4, platelet basic 
protein, protein activating the connective tissue 3, RANTES (Regulated on Activation 
Normal T Cell Expressed and Secreted) and platelet factor 4 [66]. These peptides have 
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been linked to the antimicrobial action against methicillin-susceptible Staphylococcus 
aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), Escherichia 
coli, Candida albicans, Cryptococcus neoformans[67].  In tuberculosis and in 
Pneumocystis carinii and Helicobacter pylori infection RANTES levels were also noted to 
be increased [66, 69]. When the antimicrobial properties of proteins and peptides secreted 
and collected in platelet gel supernatants were studied [72] dissimilar bactericidal effect 
against different bacteria strains (Acinetobacter baumannii, Pseudomonas aeruginosa and 
Staphylococcus aureus) were detected. In fact, platelet gel supernatants showed strong 
antimicrobial property against A. baumannii, moderate activity against S. aureus and only 
a low bactericidal activity was observed in ex vivo skin model, but no bactericidal effect 
was detected in vitro against P. aeruginosa [73, 74].  
Another indirect mechanism of how platelets contribute to the host defense is by inducing 
expression of antimicrobial protein in other cells. It has been reported that platelet-derived 
growth factors induce the expression of peptide human β-defensin-2 in keratinocytes [75]. 
Human β-defensin-2 has been advocate to be one of possible contributors to the inhibitory 
effect of PRP against Gram + and Gram – bacteria tested in an in vitro study [76]. Also, 
platelets facilitate bacterial clearance through the internalisation of the pathogens [68, 71, 
77]. The mechanism of action has not been clearly understood, but it is known that once 
activated by various stimuli, such as bacterial lipopolysaccharide, platelets can modify 
their shape from spheroid cells to cells with pseudopods. Changing their shape, they will 
gain the capability to interact with pathogens and contribute to the production of reactive 
oxygen species (ROS) [70, 78, 79]. Moreover, platelets are capable to enhance neutrophils 
locomotion, phagocytosis and ROS production [80-82].   
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It is reasonable to assume that when leucocytes are included in a PRP, their presence 
contributes to the antimicrobial effect detected in PRP preparation [65, 83, 84]. In most of 
the published literature on PRP, the presence of leucocytes has been largely neglected. It is 
known, though, that in the classical 2 steps PRP preparation procedure and when the 
commercial gravitational platelet separation system is used, a significant amount of 
leucocytes are included in the final preparation. When the composition of L-PRP attained 
by these preparation protocols was studied, granulocytes, T lymphocytes, B lymphocytes, 
and monocytes were found [85]. Thomsen et al. [86] investigated the phagocytic fitness of 
leucocytes entrapped in a multilayer matrix of fibrin and platelets. The authors observed 
that the neutrophils included in this preparation were active and capable of chemotaxis, 
phagocytic activity, and respiratory burst. Interestingly, the authors contradicted the 
general assumption that neutrophils have a short lifespan of less than 24 hours.  
Neutrophils, in fact, showed reduced but still present oxidative burst after 7 days, 
confirming another study’s finding revealing a neutrophil lifespan of more than 5 days 
[87].  
Within the family of granulocytes, neutrophils are crucial components of the immune 
system as a first line defense against bacteria, yeats and fungi. Neutrophils migrate to the 
infection site and exert their antimicrobial action through phagocytosis and the microbes 
are incorporated into the phagosome. Granules present in neutrophils contain several 
antimicrobial peptides, proteins, and enzymes, such as lactoferrin, cathelicidins, 
azurocidin, bactericidal/permeability-increasing protein, defensins, phospholipases A2 
[83]. The content of granules is released once the activated neutrophils have migrated to 
the infection site, the microbe has been internalised and included in the phagosome. The 
microbe is therefore exposed to a mixture of antimicrobial proteins and enzymes. Through 
 14 
the rapid release of ROS, superoxide radical and hydrogen peroxide, (oxidative burst) 
internalised particles can be degraded. Myeloperoxidase (MPO), one of the enzymes stored 
in the granules further, contributes greatly to the bactericidal activity. MPO in fact, 
catalyses the reaction between chloride ion and hydrogen peroxide enable the  production 
of hypochlorite, a strong bactericidal agent [88].  
In PRP preparations T and B lymphocytes can be present and are the major contributors to 
the adaptive immune response, a pathogen-tailored response. B cells are responsible for 
humoral immunity and their antibodies opsonise the bacteria so that it can be recognised 
by phagocytes and removed. T cells are instead involved in cell-mediated immunity 
through the production of cytokines and the release of enzymes included in granules as 
well as direct killing of virus infected cells [71]. 
Various published studies have now acknowledged the antimicrobial properties of PRP and 
L-PRP preparations [65]. Results are promising but also often dissimilar. The diversity of 
outcomes is likely due to the large variability of experimental conditions, the methodology 
used to prepare PRP, the inclusion or exclusion of leucocytes within the preparations, and 
the activation method of the preparation. The bacterial growth inhibition is mainly detected 
from the first hour of the PRP application. Antimicrobial effects of PRP preparation have 
been recorded against periodontal disease–associated bacteria (Porphyromonas gingivalis, 
Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleate) [89] and against 
oral cavity microorganisms (Enterococcus faecalis, Candida albicans, Streptococcus 
agalactiae, Streptococcus oralis and Pseudomonas aeruginosa) [90]. PRP has also been 
shown to have antimicrobial activity against Staphylococcus epidermis [91],  
Staphylococcus aureus [91-93],  Escherichia coli [93, 94]. Contradictory results have been 
published against other strains. Microbicidal effects of PRP against Klebsiella pneumoniae 
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and Pseudomonas aeruginosa were noted in Mariani et al. [94]  study but not in the study 
conducted by Bielicki et al. [93] when L-PRP preparation was tested against the same 
strains.   
Which components of PRP preparation contribute to the antimicrobial effect seen is still 
under debate. A few studies showed that the antimicrobial effect of PRP is independent of 
platelet concentration [91, 93, 95].  As PRP preparation also incorporates plasma 
components, complement has been suggested to be one of the major contributors to the 
antimicrobial effect of PRP preparation. The complement system is in fact, a major 
supplier of innate defense acting in both antibody-dependent and -independent immunity 
[96]. Studies suggest that the plasma complement rather than platelets or leucocytes 
contributes to the antibacterial effect [95, 97].  
It is important to point out that studies so far published, have mainly tested the 
antimicrobial properties of PRP against planktonic cultures of bacteria and have not 
considered effects on bacteria biofilm formation. Bacteria in biofilms have become an 
emerging and serious clinical issue as a frequent cause of persistent infection [98, 99]. 
Biofilm is an aggregate of bacteria where pathogens are able to produce an extracellular 
polymeric substance (EPS) matrix. Bacteria initially adhere to a surface or to each other 
and consequentially, through a self-release of quorum-sensing molecules, start producing 
EPS [100]. Compared to a single free-floating bacteria life-style, living in biofilm seems to 
be convenient for bacteria for several reasons: exchange of genomic materials, a way to 
share food, protection to unfavourable environmental conditions, including when bacteria 
have to fight against antimicrobial, antibiotic and innate human defenses. It has well 
recognised that biofilms of Pseudomonas aeruginosa are one of the major mechanisms 
responsible for chronic infections such as otitis media[101], cystic fibrosis [102], 
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periodontal disease [102, 103], skin infection [104], burns [105] and recalcitrant wounds 
[106, 107].  
To the best of our knowledge, only two studies have been conducted testing the effect of 
PRP against biofilm [86, 108]. Rozalski et al. showed bactericidal effect of ‘expired’ 
platelet-rich plasma against planktonic and biofilm cultures of S. aureus, whilst Thomsen 
et al. showed that leucocytes included in a multi-layered rich platelet-rich fibrin patch 
(LeucoPatch®) were able to control bacterial growth of an alginate-embedded P. 
aeruginosa model, that mimic the biofilm mode of growth.  
1.5 Study aims 
 
I. To perform a systematic review of the literature on the specific contribution of 
leucocytes included in PRP preparations in terms of their antimicrobial properties. 
II. To define methods of preparation of PPP, PRP, L-PRP and to demonstrate ability to 
produce consistent results. 
III. To evaluate in vitro antimicrobial effects of different PRP preparations against most 
frequent, resistant bacteria present in burn wounds (Staphylococcus Aureus, 
Acinetobacter Baumanni, Pseudomonas Aeruginosa testing the capability of the 
preparations to reduce bacteria growth and prevent biofilm formation.   
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In this review the aim was to review the literature on the contribution of leucocytes 
included in PRP preparations in terms of their antimicrobial properties. In view of the vast 
variation and heterogeneity in terms of classification, preparation methodologies, and 
activation methods, the studies included in this review have been analysed in terms of the 
methodology used i) for the preparation of L-PRP, and ii) to study the antimicrobial 
activity. This should help to inform clinical practice and additional research in this 
promising field.  
2.2 Methods 
  
2.2.1 Data Sources 
A literature review of publications was performed by two independent reviewers in May 
2016 in the Ovid MEDLINE, PubMed (1946-2016) and EMBASE (1974-2016) database. 
In addition, the reference lists of all identified articles were examined to identify relevant 
papers that were not captured by electronic searches. MeSH Terms, Headings with 
Boolean operator for PubMed search were:  ["platelet-rich plasma"[MeSH Terms] OR 
"platelet-rich"[All Fields] AND "plasma"[All Fields]] OR "platelet-rich plasma"[All 
Fields] OR ["platelet"[All Fields] AND "rich"[All Fields] AND "plasma"[All Fields] ] OR 
"platelet rich plasma"[All Fields] ] AND ["anti-infective agents"[Pharmacological Action] 
OR "anti-infective agents"[MeSH Terms] OR ["anti-infective"[All Fields] AND 
"agents"[All Fields] ] OR "anti-infective agents"[All Fields] OR "antimicrobial"[All 
Fields] ]. 
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In addition, the terms “exp Platelet-Rich Plasma/  OR “exp Platelet-Derived-Growth 
Factor/” OR the following keywords: “L-PRF” OR “L-PRP” OR “Platelet Rich Fibrin” OR 
[“PLG” AND “Platelet-Rich Plasma"] OR [“PRF” AND “Platelet-Rich Plasma"] and “exp 
antimicrobial/”  were used in MEDLINE and  EMBASE to search all articles including 
PRP and antimicrobial effect exploded subheadings. 
2.2.2 Study selection criteria 
Study eligibility was defined using the population, intervention, comparator, outcome, and 
study design approach (PICOS) [109]. The inclusion and exclusion criteria are summarized 
in Table 2.1. Study selection was performed through two levels of screening. In the first 
level, abstracts were reviewed for the inclusion and exclusion criteria. In the second level 
screening, all articles filtered through the first level were fully read and the selected 
inclusion and exclusion criteria applied. The eligibility of the studies was assessed 
independently by two authors. Discrepancies were resolved by discussion. The ultimate list 
of included articles was designated with the agreement of all the authors. To be included, 
studies needed to clearly address the leucocyte inclusion in the composition of PRP and 
haematology value reported. Comment, case reports and review papers were excluded. 
Studies with duplicate publication were only included once, using the most recent 
publication. Only in vitro and human studies were included.  Animal studies were excluded 
in this review, since i) none of the animal studies extracted from the literature search 
compared PRP preparations including leucocytes to preparations only including PRP,  ii) 
the environment in an animal model is different to a human model and does not translate to 




Table 2.1. Inclusion and exclusion criteria for literature review  
 






Clear inclusion of leucocytes in PRP/L-
PRP preparation 
Cellular components into PRP/L-
PRP preparation not stated 
COMPARATOR 
Any preparation with negligible 
concentration of Leucocytes 
No comparators 













2.3.1 Articles included 
The literature search yielded a total of 686 articles.  From a first screening of the titles and 
abstract and removal of duplicates, 643 citations were found to be not relevant to the topic 
or removed as they were duplicates. Therefore 43 articles progressed to the second level of 
screening. After retrieval of full text, review of each article, and application of inclusion 
and exclusion criteria and addition of 1 article discovered by review of references, 11 
papers were included into the final analysis (figure 2.1 and table 2.2).  














686 From database 
(Medline/ Embase: 221 articles, PubMed: 465 
articles) 
First level screening  
482  papers after removal of duplicate 
First level screening  
43 papers after screening by title and abstract 
Second  level screening  
10  papers fitting inclusion criteria 
Second level screening  
1  paper  from review of reference 
11 papers included  
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Antimicrobial effect: +              No antimicrobial effect: - (Compared to whole blood) 
          Parameter  
tested 
Comparators  
In vitro studies 
Bielecki 
TM  
et al.  























  PRG1 Thrombin2 
  
MSSA + - 
MRSA ++ - 
E. coli (ESBL 




E. faecalis - - 
  K. pneumoniae - - 
  P. aeruginosa - (evident growth) - 
  1. PRG: Platelet Rich Gel: PRP activated with bovine thrombin (1600 U/ml bovine thrombin in a 10% calcium chloride solution, Trombina 400: Biomed, 
Lublin, Poland), 2. Trombina 400: Biomed, Lublin, Poland 
Moojen 
DJ  











3200 rpm for 19 
min 













  PLG-AT1 PLG-BT2 PRP PPP PBS 
  




Peak after 4 h 
+ 





Peak after 8 h 
- 
For the 24-h period PLG-AT larger antimicrobial activity compared to PRP and 
PPP, but not PLG-BT. After 4 hour bacterial regrowth, reaching after 24 hours 





1.PLG-A: Platelet-leukocyte gel with 50 IU/ml autologous thrombin (from PPP + activAT™ system ethanol reagent solution (Sorin Group, Mirandola, Italy), 2. 
PLG-BT:  Platelet-leukocyte gel activated with 500 IU/ml bovine thrombin 
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Anitua E  
et al. 
BTI System (IV, 
Vitoria Spain) 




















  F11 F32 F3+Leucocyte3 Control4  
  
MSSA + + + - 





MRSA ++ + ++ - 
  MSSE +/- +/- + - 
MRSE + + + - 








All preparations resulted in decreases in bacterial numbers, with maximum decreases seen after 4 
hours of incubation. The effect was bacteriostatic, with rebound and growth for all bacterial strains 
after 8 hours.  
  
  










frozen at -20°C 
until use, and all 
other 
preparations 
made from this  
 
PPP: 6000g for 
30 min then kept 
frozen at -20°C 
until use. 


















  PPP PRP PG1 S/D-PL2 Broth PBS  HI3 
  
E. coli  
(ATCC 8739) 
++ ++ ++ ++ - - - 
No colony available for 48h  
Zone of inhibition detectable  










S.  epidermidis 
(ATCC 12228) - - - - - - -   
  P. aeruginosa  
(ATCC 10147) 
D17++ D17++ D17+/- D17++ 
- - - 
  






D17++ D17++ D17+ D17++ 
- - -   D28 + D28 ++ D28 - D28 ++ 
  Zone of inhibition detectable     
  S. aureus  
(ATCC 29213) 
D17+ D17+ D17+/- D17+ 
- - -   D28 + D28 + D28 - D28 + 
  E. cloacae  - - - - - - - 
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  (ATCC 13047) 
  B. cereus  
(ATCC B 
11778) 
- - - - - - -     
    B. subtilis  
(ATCC 21778) - - - - - - -       
  1: PG: Platelet gel , PRP activated with Calcium chloride 23mmol/L/L for 30 minutes at 22°C, 2. S/D-PL (solvent/detergent-treated virally inactivated PLT 
concentrate lysate)., 3 HI Heat inactivated preparations: PRP, PPP, PG and S/D-PL inactivated through heat treatment at 56°C for 30 minutes. The supernatants 
were then kept frozen at -20°C until use. 7. D1: donor 1, 8. D2: donor 2 
Chen L  





to produce PRP 
and PPP:  313 g 
for 4 min then 
1252 g for 6 
min. 

















  PRP APG1 APG-APO2 PPP PBS 
  
S. aureus  
(ATCC 6538) +/- ++ ++ +/- - 
 
  
Reduced bacterial counts observed in the APG and APG-APO groups in the first 
four hours, when compared to the PBS group. Counts in APG and APG-APO 
lower than PRP and PPP in the 24 hours. 
  
  E. coli  
(ATCC8099) + + + + -   
  P. aeruginosa 
(ATCC 15422) + + + + -   
  The ‘antibacterial rate’ varied between bacteria: S. aureus (61-77%), E. coli (61-91%), and P. 
aeruginosa (<20%).  
  1.APG: Autologous platelet-rich gel,  PRP activated with thrombin and calcium gluconate, 2. APG-APO: APG combined with apocyanin 
Wu X  





spins at 1740 




of part of the 
















  PRP PLF1 PPP Bioseal2 PBS 
 E.coli (ATCC  
25922) + + 
max decrease 
at 0-4 h 
+  
max decrease  
at 0-4 h 
- - - 




  Zones of 
inhibition: 









PRP (10 000 







yes yes no no no 
  PPP 
 
 










at 0-4 h 
+  
max  decrease  
at 0-4 h - - - 
  
      Zones of 
inhibition:  
yes 
Zones of  











      





at 0-4 h 
+  
max decrease  
at 0-4 h 
- - -       
  
















  1.PLF: Platelet-leucocyte fibrin obtained by preparing platelet-rich thrombin (through adjusting the pH), and cryoprecipitate (through freezing/thawing of PRP), 
and activated by thrombin from the same donor 2. Bioseal® (commercial fibrin glue)  
Intravia  
et al.  







15 min at 3200 
rpm . PRPLP2:  
centrifuged for 5 
















  PRPHP1 PRPLP2 Whole  Blood3 PBS Cefazolin  
  MSSA + + - - + 
MRSA + + - - + 





MSSE + + - - + 
  
  
P. acnes + + - - - 
Both PRPLP and PRPHP: Significant decrease in bacterial growth for MSSA, S. epidermidis, 
MRSA and P. acnes compared to the whole blood control group at 8 hours. After 24 hours, there 




 1.PRPHP: PRP with high platelets and WBC,  2. PRPLP: PRP with low platelets and WBC, Pre-treated with autologous conditioned plasma (ACP) Double 
Syringes (Arthrex Inc., Naples, FL) 
Lopez C 





















spins, one at 
120g for 5 min, 
and then at 240g 
for 5 min.  
 
Plasma:3500g 












29213) +++  +++  +++  +++  - - +++  
   
MRSA (ATCC 
43300)  ++ + + + - - +++  
      At 24 h MSSA: growth “inhibited in order of importance by PRP, plasma, LPP, LPG and PRG” 
At 24 h MRSA: LPG and plasma better bacteriostatic than IP.  growth similar in PRP, PRG and 
LPP when compared to IP 
  1.PRG, pure platelet-rich gel (activated with calcium gluconate (in a 1:10 ratio with 9.3 mg/ml),2. LPP leukocyte-poor plasma, 3. LPG leucocyte-poor plasma 
gel (activated with calcium gluconate (in a 1:10 ratio with 9.3 mg/ml), 4.IP: heat-inactivated plasma, prepared by heating the plasma at 65ºC for 30 minutes to 
denature its complement, 5. Positive control group (Muller-Hinton broth with bacteria), 6. Negative control group (composition not stated) 
Mariani 
E  






centrifuged  at 
730 g for 15 
min, and then at 







460 g for 8 min 













  L-PRP1 P-PRP2 L-PRP cryo3 Negative control4 
  
E. coli (ATCC 
25922) 
+ + + - 




`S. aureus  
(ATCC 29213) 
+ + + -   
  L-PRP 
cryo3 






+ + + -   
      K. pneumoniae 
(ATCC 700603) 
+ + + -       
      E. faecalis 
(ATCC 29213) 
+ + + - 
  1.L-PRP: Leucocyte and platelet rich plasma,2. P-PRP: pure platelet rich plasma,3. L-PRP cryo: prepared from L-PRP which was frozen at −30 °C for 2 h and 
then thawed to obtain the cryopreserved fraction, Negative control: TSB broth.  P-PRP, L-PRP and L-PRP cryo were activated with 10 % calcium chloride 
(final concentration of 22.8mM) 
Thomsen 







In vitro  
Blood from 
 Leucopatch Control1 






3000 g for 8 
min and 


















5x 108 CFU/ml 
  
P. aeruginosa 










model in disc 
++ - 
Burst assay, phagocytosis assay, migration assay, biofilm killing assay and fluorescence in-situ hybridization 
(FISH) assay described in text 
1.Control: buffer + P. aeruginosa 
In vitro and in vivo studies 
Li H  





spins, one at 
300g for 10 min, 
and the second 
at 3,000g for 15 
min.  
Supernatant 






















In vitro 6 
rabbits  
  PRP gel1 PPP gel In vivo study: one group 
treated with PRP gel, and 
the other with PBS (control). 
Samples from around the 
implant collected at 
euthanasia for 
microbiological assessment.   
Compared to the control, 
there were significantly 
fewer bacterial colonies in 
all the samples in the PRP 
gel group. 
  MSSA + (200 IU/ml thrombin) - 
 
  
MRSA + - 








  Pseudomonas  - - 
  E. coli - - 




at 12-24 h 
  1.PRP gel: Activated using different concentrations of Bovine thrombin (20, 100, 200 IU/ml) and 10% calcium chloride 
Legend:  
PBS: phosphate buffered saline , MSSA: Staphylococcus aureus both methicillin-sensitive, MRSA: Staphylococcus aureus both methicillin-resistant (MRSA), E. Coli: 
Escherichia coli- ESBL: Extended Spectrum Beta Lactamase, and E. coli non-ESBL, E. faecalis: Enterococcus faecalis, E. cloacae: Enterobacter cloacae, K. Penumoniae: 
Klebsiella pneumoniae, P. aeruginosa: Pseudomonas aeruginosa, MSSE: Staphylococcus epidermidis, B. cereus: Bacillus cereus, B: subtilis: Bacillus subtilis, S. pyogenes: 
Streptococcus pyogenes, N. gonorrhoeae: Neisseria gonorrhoeae, P. acnes: Propionibacterium acnes, Group A Strep: Group A Streptococcus 
2.3.2 Study design 
All 11 papers included in the review were in vitro studies where various amounts of blood 
were drawn according to the requirements of the individual L-PRP preparation method 
(varying from 53 ml to 300 ml of blood from each donor). Blood was drawn from healthy 
human volunteers in seven studies [86, 91-93, 97, 110-113], from patients with diabetic 
ulcers in one study [114], from horses in one study [115], and from rabbits in one study 
[116]  There was one study that included both in vitro and animal study. As for inclusion 
criteria, only the in vitro studies have been further analysed [116].  
2.3.3 Parameters tested 
The antimicrobial activity of L-PRP was tested against different bacterial strains including 
Staphylococcus aureus, both methicillin-sensitive (MSSA), and resistant (MRSA), 
Escherichia coli, Enterococcus faecalis, Enterobacter cloacae, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Staphylococcus epidermidis, Bacillus cereus, Bacillus subtilis, 
Streptococcus pyogenes, Neisseria gonorrhoeae, and Propionibacterium acnes. In addition 
to the antimicrobial properties of the biomaterial, other leucocyte and platelet parameters 
were also included in some studies. Moojen et al. [92] for example aimed to evaluate the 
contribution of leucocytes with their oxidative killing action, and therefore included in their 
study measurements of myeloperoxidase (MPO) activity and MPO release. The authors 
found that MPO was gradually released by thrombin activated PRP and not activated PRP 
preparations in the first hours. No significant differences were detected in the MPO activity 
between the different preparations, nor was there a correlation between MPO concentration, 
activity and bacterial killing. To test the antimicrobial contribution of leucocytes in the 
preparation, Chen et al., [114] used apocynin, an inhibitor of NADPH oxidase activity, to 




antimicrobial activity of the preparation where leucocyte function was inhibited compared to 
an activated L-PRP preparation.  Release of different growth factors at various incubation 
times were also measured in one study. PF-4, TGF-β1, and  PDGF-BB were measured [115] 
in order to test the possible antimicrobial contribution of different concentration of growth 
factors within PRP preparations and the ability of bacteria to denature or reduce growth 
factors levels. Measurement of complement and antibody levels were also included in the 
study conducted by Wu et al. [110]. Using immunoassay kits, Mariani et al. [113] measured 
proteins released by PRP preparations, such as ‘Macrophage Inflammatory Protein’ (MIP)-
1α (CCL3), ‘Regulated on Activation Normal T Expressed and Secreted protein’(RANTES), 
GRO-α, Interleukin (IL)-8, Interleukin (IL)-6, neutrophil-activating protein (NAP)-2, and 
stromal cell-derived factor (SDF)-1α. When the concentration of the proteins and the 
bacteria growth inhibition was tested, the proteins showed strong antimicrobial potential. 
Other parameters tested were the contribution to the antimicrobial effect of activated (with 
different activators) and not activated PRP [97, 110, 114, 115]. In Li et al. [116] various 
concentrations of bovine thrombin were used to activate L-PRP and used to assess the role 
of thrombin in the antimicrobial properties of PRP.  
2.3.4 Method of preparation of L-PRP and its influence of the haematological values of 
leucocytes and platelets 
The methods of L-PRP preparation used in the selected studies were considerably different, 
as shown in Table 2.2: single or double centrifugation, different platforms, different spin and 
centrifugation values (‘g’ standing for multiples of earth gravitational field and ‘rpm’ 
standing for rotation per minute) and different centrifugation duration times. Not 
surprisingly the variation within the methods of preparation caused variations in the 




studies the processing methods resulted in enrichment of platelet concentration of the PRP, 
ranging from as low as two-fold [91, 115, 117] up to ten and eleven-fold in Li et al. [116] 
and Wu et al. [110].[116]  There was also a wide variation in the concentration of leucocytes 
in the L-PRP after processing, varying from a minimal concentration of leucocytes used  in 
an in vitro study (3.9-fold decrease from whole blood) [110]  to a maximal concentration of 
4-fold enrichment tested in Li et al. None of the studies specified the differential white 
blood counts, so the relative percentage of each type of white blood cell in the L-PRP 
preparations is unknown. The viability and function of leucocytes after the PRP processing 
was assessed in the study conducted by Moojen et al. [92]. Here the authors measured MPO 
concentrations after a single step centrifugation method used to prepare L-PRP, and found 
that neutrophils and monocytes were not only viable but biologically active as shown by the 
rapid increase in MPO concentration detected shortly after the addition of L-PRP to the 
bacterial culture.  
2.3.5 Activation of L-PRP 
Of the 11 studies, 9 prepared L-PRP as a gel form by activating platelets to release their 
granule components. L-PRP was activated by different activators including a combination of 
calcium chloride and bovine thrombin, or calcium chloride alone, or autologous thrombin 
alone or calcium gluconate alone (Table 2.2). Only one study evaluated the antimicrobial 
effect of L-PRP in its pure, inactivated form [111].  
2.3.6 Microbiology assay 
The 11 studies included were very similar in terms of the methodologies used to test the 
biomaterials. Nine of the 11 (Table 2.2) used a bacterial killing assay, whereby bacterial 
cultures and the biomaterials were mixed together, incubated under agitation, and aliquots 




assessment of bacterial counts (in terms of CFU/ml). The evaluation of the zone of 
inhibition (Kirby-Bauer disk-diffusion method) was used in 3 studies [93, 97, 110]. As well 
as the methodologies being similar, there was good concordance in terms of the bacterial 
isolates tested, with 9 of the 11 papers testing S. aureus, and half of the papers testing Gram 
positive organisms only.  
2.3.7 Antimicrobial outcomes  
Outcome of in vitro studies  
The first paper addressing the antimicrobial activity of a PRP preparation with a clear 
recognition of the inclusion of leucocytes, was the study published in 2007 by Bielecki et al. 
[93]. The authors conducted an in vitro study drawing blood from healthy human volunteers 
to evaluate the antimicrobial activity of PRP activated with bovine thrombin in a 10% 
calcium chloride solution (PRG, Platelet Rich Gel) against the most frequent bacteria 
responsible of wound and bone infections: MSSA, MRSA, E. coli (Extended Spectrum Beta 
Lactamase, ESBL) and non-ESBL, K. pneumoniae (ESBL), E. faecalis and P. aeruginosa. 
High concentrations of both platelets and leucocytes were obtained (increased by 760% and 
790% respectively) using a single centrifugation method. The antimicrobial activity of the 
L-PRP preparation was determined using a Kirby-Bauer disc-diffusion method, and showed 
different effects for different strains, with strong antimicrobial activity detected against 
MSSA, MRSA and  E. coli, whilst no bactericidal activity was found against E. faecalis, K. 
pneumoniae and P. aeruginosa. Alarmingly the addition of L-PRP to P. aeruginosa led to an 
actual increase in growth. Even though the objective of the study was not specifically to 
evaluate the antibacterial activity of different concentrations of platelets or leucocytes, the 




activity and the value of platelets and leucocytes in the blood and the platelet-rich plasma 
was detected.   
The study conducted by Moojen et al. [92] was the first attempt in recognising the specific 
contribution of leucocytes in L-PRP preparations. The authors used a semi-automated table 
top centrifuge to obtain PRP, reaching high concentrations of both platelets and leucocytes 
(platelets and leucocytes more than 7-fold and 3-fold enrichment, respectively). L-PRP was 
activated with either autologous or bovine thrombin, resulting in a preparation referred by 
the authors as PLG-AT or PLG-BT (Platelet-leucocyte gel autologous (AT) or bovine 
thrombin (BT). Other comparators were PPP (Platelet Poor Plasma), PRP (Platelet Rich 
Plasma) and PBS (phosphate buffered saline), the latter which acted as a control. The 
different preparations were used to test antimicrobial activity against MSSA using a 
bacterial killing assay. Even though all the four blood preparations showed antimicrobial 
activity, the PRP containing high concentrations of both platelets and leucocytes, and 
activated with autologous thrombin (PLG-AT), proved to be the most antimicrobial (and to 
give the longest duration of effect) compared to PRP, PPP and PRP-BT. In this study non-
activated PRP and PPP also exhibited some antimicrobial activity, but with a more delayed 
effect. Autologous activated PRP showed the largest effect for the entire 24 hours. There 
were no preparations resulting in 100% efficiency of bacterial killing. In order to explore the 
contribution of leucocytes to the antimicrobial properties shown by the L-PRP preparation, 
myeloperoxidase (MPO) activity and MPO release at different time points of incubation 
were measured. MPO was gradually released in PLG-AT, PLG-BT and PRP preparations in 
the first few hours. Interestingly though, no significant differences were detected in the 
MPO activity between the four different preparations, nor was there a correlation between 




the stronger antimicrobial effect found with the PLG-AT preparation is likely due to the 
effect of thrombin acting on the antimicrobial peptides released by platelets rather than 
effect of leucocyte activation.  
Different preparations including low and high concentrations of platelets, and inclusion or 
exclusion of leucocytes, were used by Anitua et al. [91] to evaluate the bactericidal effect of 
the different blood products against four bacterial strains. Here a bacterial killing assay was 
performed to test the antimicrobial activity of PRP products against MSSA, MRSA, 
methicillin-sensitive S. epidermidis (MSSE) and resistant S. epidermidis (MRSE). The 
different fractions obtained from plasma after a single centrifugation step were: F1 (plasma), 
which contained a 1-fold enrichment of platelets and no leucocytes compared to whole 
blood, F3 (PRP) containing 2.5-foldenriched platelets and no leucocytes, and 
F3+leucocytes:1.8-fold  enrichment of platelets  and 3.9-fold enrichment of leucocytes.  The 
authors found that after four hours all the fractions revealed bacteriostatic properties against 
MSSA and MRSA and MRSE. The preparation including leucocytes was revealed to be 
superior against MSSE, where it was the only fraction able to reduce the growth in the 
experiment.   
In order to explore the nature of the antimicrobial activity of PRP and specifically to 
investigate which components exert this effect, Burnouf et al. [97] tested the effect of 
different blood preparations against eight strains of wound bacteria (four Gram positive and 
four Gram negative bacteria). The authors compared PRP (containing leucocytes), calcium 
chloride activated PRP (PG: Platelet Gel), PPP (platelet poor plasma), solvent/detergent-
treated PLT lysate (S/D P-L) and complement inactivated preparations . All the preparations 
were immediately frozen and kept frozen at ≤-20°C until use. PRP was processed by 




platelets and 1-fold for leucocytes. The authors performed a bacterial plate assay followed 
by colony counting, and assessed log reductions at 3 hours when the test sample was 
compared to the PBS controls. P. aeruginosa, K. pneumoniae, and S. aureus all showed an 
initial log reduction in bacterial numbers 3 hours after spiking into the different 
preparations, however the reductions were lowest with the PG, and bacterial regrowth was 
seen at 48 hours with all preparations. The preparations were most effective against E. coli, 
where there was a large inactivation of bacteria (7.51 to >9.01 log), and no viable colonies 
for 48 hours after spiking. Furthermore, similar antimicrobial activity was seen in different 
preparations regardless of the concentrations of the platelets and leucocytes. As the PG 
preparation appeared to have the lowest antimicrobial effect on these strains, it seems that 
the use of calcium chloride for activation of coagulation could have decreased the 
bactericidal property of the PRP.  Although there were some antimicrobial effects, none of 
preparations were able to inhibit, B. cereus, B. subtilis, and S. epidermidis. Reassuringly, 
complement-inactivated control preparations did not show any antimicrobial activities. 
Having taken all into account, the authors concluded that plasma complement, rather than 
specifically platelets or leucocytes, are the elements responsible for the antimicrobial 
activity seen against E. coli, K. pneumoniae, and S. aureus.   
Chen et al. [114] investigated the in vitro antimicrobial activity of APG (autologous platelet-
rich gel)  extracted from the blood of patients with diabetic dermal ulcers,  against the most 
common bacteria found in diabetic chronic wounds: S. aureus, E. coli and  P. aeruginosa. 
To mitigate any confounding effects of previous IV antibiotics that the patients may have 
received as part of routine care, the blood for the PRP preparation was drawn from patients 
8-12 hours after antibiotic administration.  PRP was obtained through a double step 




preparations were: APG, PRP (inactivated), PPP, and APG-APO (autologous platelet gel 
with apocyanin). Apocyanin is an inhibitor of NADPH oxidase activity, and is thus a way to 
study L-PRP antimicrobial activity, whilst excluding the possible antimicrobial contribution 
of leucocytes producing superoxide. PBS was used as control. Both PLG and APG-APO 
were effective in reducing the bacterial counts of S. aureus compared to the PBS control in 
the first four hours, and were more effective during 24 hours compared to PRP and PPP. 
Since the APG, APG-APO and PRP preparations showed antibacterial effects against E. coli 
and P. aeruginosa compared to PBS, but there was no effect with PPP, the authors attribute 
the antimicrobial effects seen to the prior IV antibiotics administered to the patients rather 
than the biomaterial preparations. The authors concluded that the antimicrobial activity seen 
against S. aureus is likely not due to the inclusion of leucocytes in PRP preparation, as APG 
and APG-APO showed a similar antibacterial effect. It is thought that the activity may be 
attributable to the thrombin and calcium gluconate used to activate the platelets. 
 In order to test the antimicrobial activity against Gram negative bacteria that are commonly 
present in enterocutaneous fistula tracts (including E. coli, P. aeruginosa and K. 
pneumoniae), Wu et al. [110] compared three different biomaterials,  and a commercial 
fibrin glue called Bioseal®. Blood drawn from 14 healthy volunteers was centrifuged and 
processed to obtain: PLF (platelet-leucocyte fibrin) which is a preparation containing a high 
concentration of platelets (10-fold enrichment from whole blood) and low leucocytes (3.9 
fold decrease from the baseline) which is activated with thrombin; PRP (similar 
concentrations of platelets to whole blood and 3.9 fold decrease in leucocytes from the 
baseline) and PPP (poor platelet concentration and no leucocytes). The Kirby-Bauer disc 
diffusion test and bacterial killing assays were used to compare the antibacterial activity of 




C3, C4) were measured in PLF, PRP and PPP and no significant difference was found 
between the different preparations.  For the microbiological assays a greater antibacterial 
effect was found in with PRP and PLF compared to PPP. However, it was noted over time 
that PLF seemed to lose its antimicrobial effect more than PRP (although this was not 
statistically significant). The commercial fibrin glue (Bioseal®) did not show any 
antimicrobial effect. For the bacterial killing assay, the effect seemed only bacteriostatic, 
with the maximum killing of bacteria observed in the first four hours, followed by regrowth 
up to peak numbers at 24 hours. The antimicrobial activity against P. aeruginosa was dose-
dependent, requiring higher concentrations of the PLF preparation than those that were 
effective for the other two bacterial species. In the in vitro study conducted by Intravia et al. 
[111], different PRP preparations with low and high concentrations of platelets and 
leucocytes were tested to verify the antimicrobial properties against bacteria commonly 
found in arthroplastic surgery (MSSA, MRSA, S. epidermidis (MSSA) and 
Propionibacterium acnes). Two different preparations were obtained using different g 
values and centrifugation duration, along with commercial systems (Table 2). The 
preparations contained low (PRPLP), or high (PRPHP) concentrations of platelets and 
leucocytes, and both showed a significant decrease in bacterial growth at 8 hours for all of 
the bacterial samples when compared to the controls. PRP rich in leucocytes and platelets 
(PRPHP) seemed to give a superior decrease of S.epidermidis and P.acnes at 8 hours 
compared to the preparation with negligible inclusion of leucocytes and lower platelets 
(PHPLP). Also, at 1 and 4 hours after MRSA incubation, the preparation enriched with 
leucocytes (PRPHP) showed a stronger growth inhibition than the leucodepleted biomaterial 
(PRPLP).  After 24 hours, significant inhibition was still seen for MSSE, MRSA, and P. 




Lopez et al. [115], compared different preparations of PRP, (with low and high levels of 
leucocytes, activated or in their pure form), in terms of their antimicrobial properties against 
MSSA and MRSA. Blood was drawn from 18 healthy horses, and using double 
centrifugation, the authors obtained a range of preparations containing different 
concentrations of platelets and leucocytes. These were enriched respectively by 1.64 and 2-
fold from the blood baseline in the PRP preparation whereas in the LPP (leucocyte poor 
plasma) preparation, the leucocyte count was negligible. The pure form of these two 
products was also compared to the activated form (activated via calcium gluconate), and to 
plasma and to heat-inactivated plasma (IP). With the exception of IP, at six hours, all blood 
components, significantly inhibited bacterial growth. The non-activated form of PRP 
showed a better bacteriostatic activity against MRSA when compared to the activated form 
(LPG: leucocytes-poor plasma gel) and plasma. MSSA showed higher sensitivity to the 
treatments than MRSA, and PRP against MSSA showed the highest bactericidal effect 
followed by plasma, then LPP, LPG, and PRG. Against MRSA, at 6 hours PRP was again 
the preparation showing stronger antimicrobial effect, whilst at 24 hours LPG and plasma 
had stronger bacteriostatic effect against MRSA. The release of growth factors (PF-4, TGF-
β1, PDGF-BB) by the different preparations at different incubation times were also 
measured, but no correlation between bacterial counts and leucocytes, platelets, PF-4, TGB-
β1, PDGF-BB was recorded suggesting that bacteria were not able to denature the growth 
factors, and that plasma components could be responsible for the antimicrobial effects 
observed.   
A recent publication by Mariani et al. [113] specifically investigated the possible 
contribution of leucocytes in a PRP preparation against different bacteria of relevance to 




pneumoniae, and E. faecalis). Two different PRP preparations (including or excluding 
leucocytes) were obtained from 150 ml of whole blood, drawn from 10 healthy donors. The 
preparation involved different centrifugation steps as shown in table 2, and resulted in L-
PRP: Leucocyte and platelet rich plasma and P-PRP: and a pure platelet rich plasma 
preparation.   Moreover, to investigate whether or not the cryo-preserved blood product 
influenced the antimicrobial effect, a third preparation was obtained by freezing the L-PRP 
preparation at −30 °C for 2 h, L-PRP-cryo preparation.  All the products were then used in 
their activated form for the experiment. As the three different preparations showed similar 
antimicrobial results (with bacterial growth inhibition effective for up to 4 hours for all the 
preparations), the authors concluded that the inclusion of leucocytes does not contribute 
significantly to the microbicidal activity of PRP. The inhibition varied between 1-4 log, 
according to the bacteria strain and experimental conditions tested.  After treatment with the 
three plasma fractions a time-dependent inhibition of bacterial growth (for up to 4 hours) 
and at low bacterial count for E. coli, and P. aeruginosa, and at higher numbers for S. 
aureus, and Enterococcus faecalis was detected. In contrast, there was not a time-dependent 
inhibition of growth with K. pneumoniae.  Generally, the quantities and abundance of the 
microbicidal proteins correlated well with growth inhibition, where higher quantities of 
proteins correspond with greater inhibition. Thomsen et al. [86] have recently published a 
study where the phagocytic fitness and bactericidal activity of leucocytes included in a 
multilayer matrix of fibrin and platelets were analysed. In the patch a high concentration of 
leucocytes is included (55 x 106/patch). The authors observed that the neutrophils included 
in this preparation are active and capable of chemotaxis, phagocytic activity and respiratory 
burst. When P. aeruginosa was mixed with leucopatch, the production of ROS of PMNs 




response was bacteria concentration-dependent.  The production of ROS during 
phagocytosis of P. aeruginosa was also tested in isolated polymorphonuclear neutrophils 
(PMNs: 107cells/ml) was tested. The resulting chemiluminescence signal was twice as high 
compared to the signal from leucopatch. When ROS production was tested for a longer time 
period of 7 days, ROS production was still observed at day 4. The chemotactic leucocyte 
migration was also investigated using transwell chambers. The authors found that the PMNs 
included in leucopatch were capable of migration towards P. aeruginosa. Moreover, 
bactericidal assays tested Pseudomonas aeruginosa in both planktonic and in an alginate-
embedded model, simulating the biofilm mode of bacteria growth. Serum-opsonized P. 
aeruginosa was exposed to leucopatch, diluted samples were plated and after 24 hours CFU 
(Colony-forming unit) were counted. Compared to control (Buffer with P. aeruginosa), 
strong reduction of colonies was observed after 20 minutes of leucopatch exposure and 
reduced further reduced after 90 minutes. Two concentration of bacteria were tested (5 x 107 
CFU/ml and 5 x 108 CFU/ml). The loss of bacteria availability was more evident (99% loss 
of bacteria with respect to the initial inoculum) when the lower concentration of bacteria 
was exposed to the leucopatch. When bacterial growth was tested in alginate beads and disc, 
mimicking a biofilm model, also antimicrobial activities of the patch were detected. The 
alginate beads and discs with Pseudomonas were exposed to leucopatch for 2 hours, 
transferred to tubes containing PBS (phosphate-buffered saline), homogenized, serially 
diluted, plated, and the next day the CFU were counted. After 2 hours, colonies count was 
reduced by 70% when simulating biofilm in form of disc when exposed to leucopatch and 
leucopatch inhibited bacterial growth completely compared to non-leucopatch control in the 





Outcome of in vitro and in vivo studies 
In vivo and in vitro studies were conducted by Li et al. [116] to test the antibacterial effect of 
PRP gel and the ideal concentration of bovine thrombin for activation of the PRP. For the in 
vitro study, a killing curve assay was used to test the effect of PRP and PPP gels against 
MSSA, MRSA, Group A Streptococcus, N. gonorrhoeae, Pseudomonas spp. and E. coli. 
PRP gel was obtained from rabbit blood, through a two-stage centrifugation process and 
activated using a range of different concentrations of thrombin in calcium chloride. Results 
were compared to PBS controls and to PPP-gel. The concentration of platelets and 
leucocytes in the PRP gel preparation was extremely high (approximately 10-fold and 4-fold 
increase from the baseline respectively), and this preparation was shown to inhibit MSSA, 
MRSA, Group A streptococcus and N. gonorrhoeae growth in the first 4 hours, after which 
an increase of growth was identified. Only high concentrations of thrombin produced 
sufficient antimicrobial activity of the PRP gel against N. gonorrhoeae. There was no 
antimicrobial activity of the PRP gel against Pseudomonas spp. and E.coli, and the PPP gel 
was ineffective for all. The in vivo study tested the antimicrobial activity of PRP gel against 
rabbits with a spinal implant-associated infection with S. aureus. The injection of the PRP 
gel increased bone formation, and decreased the bacterial counts found in the bone at 
different time points.  
2.4 Discussion  
2.4.1 L-PRP versus PRP  
Only 4 studies have specifically compared the antibacterial properties of autologous PRP in 
the presence and absence of leucocytes or L-PRP [91, 111, 113, 115]. The overall 
conclusion of the authors was that no significant difference between the two preparations 




PRP seem to be caused by either plasma and/or platelet components rather than the 
leucocytes themselves [97, 114, 115]. However, looking for results on specific bacteria 
strain, Anitua et al. [91], showed that the fraction containing a very high concentration of 
leucocytes (almost 4 times the baseline) was the only preparation able to effectively reduce 
MSSE.  Furthermore Intravia et al. [111], reported that the PRP preparations with a high 
concentration of leucocytes were superior to PRP with no leucocytes against MRSA, MSSE 
and P.acnes. Also compared to whole blood, both preparations limited bacterial growth, but 
for MSSA the preparation with leucocytes showed a longer (24 hours) inhibition of MSSA. 
Moreover, Lopez et al. [115] showed that the non-activated preparation enriched with 
leucocytes gave a better 6 hours and 24 hours  bacteriostatic effect against MSSA compared 
to preparations poor in leucocytes. In contrast, against MRSA, the activated form of the 
preparation with poor leucocytes and plasma seemed to perform better than the other 
preparations tested at 24 hours. In contrast Mariani et al. [113], concluded that ‘Leucocyte 
presence does not increase microbicidal activity of Platelet-rich Plasma in vitro’ in a study 
where the quantity of leucocytes included in the L-PRP preparation was low, no dissimilar 
from the whole blood.  Whole blood was used as a positive control by Intravia et al. [111], 
and in their study the authors showed the poor antimicrobial activity of the whole blood 
compared to the biomaterial enriched with platelets and leucocytes. Moreover, a significant 
antimicrobial effect of PRP was seen when leucocytes were at least 2-fold enriched from 
baseline [116]. To evaluate the potential antimicrobial contribution of leucocytes, Chen et al. 
[114] used apocyanin in L-PRP preparation to exclude the possible contribution of 
leucocytes producing superoxide. The authors showed similar antimicrobial activity 
regardless of apocyanin, concluding that the antibacterial effect of the biomaterial was not 




2.4.2 Activation of PRP preparations  
Results are controversial regarding the activation of the PRP preparations. Burnouf et al. 
[97], suggested that the activation of platelets by calcium chloride decreased antimicrobial 
properties against selected bacterial strains. Similarly Wu et al. [110] showed thrombin 
activated PRP preparations have less antimicrobial activity against E.coli, P. aeruginosa and 
K. pneumoniae compared to the inactivated preparations. These findings are thought to be 
due to consumption of complement during the coagulation activation. Also Lopez et al. 
[115] indicated that after 24 hours of incubation, calcium gluconate activated PRP 
preparations exhibited less antimicrobial activity against MSSA compared to inactivated 
preparations.  When the preparations where tested against MRSA, at 6 hours, the strongest 
antimicrobial effect against MRSA was again exerted by the non-activated form of the 
leucocyte enriched preparation, whilst at 24 hours the activated form of leucocytes poor 
plasma showed stronger antimicrobial effect compared to the other preparations tested. 
Controversially, other studies indicate that strongest antibacterial activity is reached 
activating PRP preparation [114] and when different concentration of thrombin were 
compared,  with the highest concentration of thrombin tested resulted exerting the strongest 
antimicrobial effect, with autologous thrombin performing better than bovine thrombin 
[116].  
2.4.3 L-PRP/PRP preparation methods and microbiology assays 
Due to the heterogeneity of the preparations and the multiple variables in the study settings, 
it is difficult to compare results of studies and reach definitive conclusions regarding the 
relevance of the leucocytes in antimicrobial activity of L-PRP preparations.  The proportion 
of the different components included in the biomaterials that exerted the strongest 




that the in vitro studies may not reflect the clinical scenario, since this environment may not 
mimic the dynamic condition of an in vivo setting where the antimicrobial properties of each 
individual components of the biomaterial may be increased, prolonged or even reduced by 
the complex interaction of cellular signals, and dynamic fluid exchange. An example of 
different results of platelet gel effects against bacteria obtained in vitro and in an ex vivo 
skin model is clearly shown in a recent published study. Edelblute et al. [72] demonstrated 
different antimicrobial performance against three strains of bacteria in different settings. No 
inhibition was seen for Pseudomonas spp. in the in vitro experiment, while inactivation of 
the same strain was detected in the ex vivo model. Moreover, as suggested by Burnouf et 
al.[97], ATCC (American Type Culture Collection) bacterial strains used in most of the 
studies, may not reflect the actual bacterial behaviour of clinical isolates. Also, different 
strains showed different responses to diverse blood products. This might due to the 
antimicrobial activity of AMPs  directly related to the intrinsic AMP susceptibility 
phenotype of the infecting bacteria strain, reflecting the point that different bacteria strains 
have dissimilar susceptibility to inhibition by platelet AMPs [118].  
2.4.5 Are the included leucocytes viable and active?  
The methodology described in the studies to centrifuge and prepare blood products should 
not theoretically damage leucocytes. It is likely that in Burnouf et al. [97], leucocytes 
included in the PRP preparation were no longer viable (Prof J. Lord, personal 
communication) (as the preparations were kept frozen until use, therefore the contribution to 
the antimicrobial effect showed by the PRP preparation is likely not due to leucocyte 
inclusion. 
In the study conducted by Moojen et al. [92] the authors found that neutrophils and 




shortly after the addition of L-PRP to the bacterial culture. Thomsen et al. [86] investigated 
the  phagocytic fitness of leucocytes included in a multilayer matrix of fibrin and platelets. 
The authors observed that the neutrophils included in this preparation were active and 
capable of chemotaxis, phagocytic activity and respiratory burst. Interestingly, the authors 
contradict the general assumption that neutrophils have a short lifespan of less than 24 
hours.  Neutrophils in fact showed reduced but  oxidative burst activity even after 7 days, 
confirming previous published revealing a neutrophil lifespan of more than 5 days [87].  
2.4.6 L-PRP in wound healing: concerns for scarring  
Mindful of all the limitations of the studies included in this review, the overall conclusion seems to 
be that the contribution of leucocytes in a PRP preparation is still poorly understood or at least not 
fully appreciated in the studies so far conducted. On the other hand, it is possible to state that none of 
the papers included in this review strongly suggest a remarkable antimicrobial effect specifically due 
to the leucocytes included in PRP preparation. Leucocyte inclusion in the biomaterial should be 
carefully further evaluated especially when the biomaterial is used for wound repair and when scar 
formation is a major concern.  Among all the factors that affect scar quality, the one that seems to 
have the greatest impact is the time that it takes a wound to heal [119]. A large body of literature 
supports the assertion that achieving wound healing within two weeks, will minimize the scarring. 
Therefore, a major focus in burns and wound healing research is to clarify the pathophysiology of the 
healing process of a wound, the risk factors related to the scarring process, and the conversion of this 
knowledge into therapeutic solutions. The use of PRP in wound healing as an accelerator of wound 
repair seems to justify its use. Several studies are now evaluating the role of leucocytes in wound 
repair and mediators and growth factors (especially TGF-β1) released by leucocytes have been 
correlated to promote scarring [59]. Their inclusion for wound healing and scar formation should 




of leucocytes are included in the preparations and which effects individually they might have in both 
antimicrobial and immune-metabolic activities.  
2.5 Conclusion   
In this review despite a number of studies showing that preparations including leukocytes have 
antimicrobial properties, there is not enough evidence to attribute this bactericidal effect to the 
presence of leucocytes in the biomaterial. PRP preparations, with or without leucocytes 
demonstrated bacteriostatic properties against the majority of the bacterial strains tested. Diverse 
strains of bacteria respond differently to PRP and L-PRP, some of them requiring the presence of 
leucocytes (MSSE), and some being dose dependent (Pseudomonas spp.). This review should form a 
groundwork for future studies to further explore the contribution of leucocytes in PRP preparation in 






CHAPTER 3. METHODS OF PREPARATION OF PRP 
PRODUCTS 
 
3.1 Introduction  
Many different procedures have been suggested to prepare PRP products and used in clinical 
settings as topical biomaterial for wound healing. PRP can be prepared using several 
different methods and this variability leads to a wide inconsistency of the final product. It 
has extensively been shown that several factors contribute to the efficacy of PRP products 
[12]: the presence and concentration of the different components included in PRP 
preparation, the methodology used to prepare the product and the methodology used to 
activate the platelets will all contribute to the antimicrobial and wound healing effect of the 
products. 
The aim of this chapter was primarily to try different methods described in the published 
literature to prepare PRP, and L-PRP and ultimately, to define a method that produces 
consistent results.  
3.2 Methods 
Taking from previously published works [8, 12, 18, 120] and from our laboratory expertise, 
different methods to prepare PRP products have been tested: single and double-step 
centrifugation techniques, different spins and different activation methods. The methodology 
that allows reproducing consistent results is here reported. 
3.2.1 Blood collection  
To obtain PPP, PRP and L-PRP, fresh blood was drawn from healthy volunteers. All 




condition under a laminar flow hood (Esco, Class II Biological Safety Cabinet, Singapore). 
A large bore needle was used to prevent activation/damage of platelets due to mechanical 
stress. In order to prevent early platelet activation and clot formation, a blood collection 
bottle pre-filled with sodium citrate was used (BD Vacutainer, New Jersey, USA). Once the 
blood was collected, the bottle was gently inverted to allow an adequate mixing of the 
anticoagulant and the blood.  
3.2.2 Determination of components in PPP-PRP- L-PRP products 
A sample of 120 µl of whole blood, PPP, PRP, L-PRP was extracted and analysed using an 
automated analyser XN-1000 whole blood counter (Sysmex UK, Milton Keynes), in order to 
obtain the measurement of platelets, leucocytes and differential counts included in each 
preparation. The analyser has a set of unique platelet parameters including three platelet 
counts: platelet impedance (PLT-I), platelet optical (PLT-O) and platelet fluorescence (PLT-
F) counts, platelet mean volume (MPV) and the immature platelet fraction (IPF). For our 
study, platelet count was recorded as PLT-F. where platelets are specifically stained by a 
fluorescent dye. It has been showed that this method had improved accuracy in platelet 
counting [121]. 
3.2.3 Preparation of blood preparations   
- for all our experiments, PPP and L-PRP preparations were obtained using a single step 
method as described below 
- for our experiments, 2 different PRP products have been used. A standard single-step 
method that allows to obtain a PRP product with a 2-fold platelet enrichment from the whole 
blood (standard method used in our laboratory) has been used to test the antimicrobial 




target the working definition of PRP suggested [12] and to achieve similar concentration of 
cells obtain in our L-PRP preparation, we decided to aim to a higher concentration of 
platelets included in our PRP preparation with a minimal concentration of cells of between 
4-fold higher than the circulating blood platelet. Therefore, when Gram negative bacteria 
were tested, we adopted the double-step method for PRP production. The two different 
methodologies used, single-step method and double-step method are described below. 
 
PPP and L-PRP preparation 
High g centrifugation (2000 g) of anticoagulated blood for 20 minutes at 21°C was used to 
obtain L-PRP and PPP. The centrifuge used was an Eppendorf Centrifuge (5804/5804 R, 
Hamburg, Germany). Under these conditions, centrifugation results in the separation of 















The lower layer is composed of red cells. An intermediate very thin layer contains 
leucocytes and platelets, also known as buffy coat, which represents the L-PRP 
preparation and finally an upper layer that con tains plasma and a poor concentration of 
platelets, the PPP preparation. 
 Firstly, the upper layer was transferred under sterile condition into an empty sterile tube 
(Corning™ Falcon™ 15 ml Conical Centrifuge Tubes, Sigma-Aldrich, Saint Louis, USA). 
Once the upper layer had been removed, the intermediate thin layer was harvested and 
transferred in an empty 15 ml sterile Corning™ Falcon™. To prevent cellular damage 
caused by mechanical stress, large bore sterile micropipettes were used to harvest the 
preparations. 120 µl of each preparation were also extracted and components measured by 
the Sysmex analyser.    
L-PRP volume yield was approximately 10% the initial volume of WB. The average ± standard 
deviation platelet count of whole blood was 211±41.8 x 106/ml, white blood count was 
7.29±1.8 x 106/ml, neutrophils 4.76±1.8 x 106/ml, monocytes 0.6±0.2 x 106/ml, lymphocytes 
1.77±0.29 x 106/ml, and red cells 4.63±0.98 x 109/ml.  
With the single-step centrifugation method described, the average ± standard deviation 
platelet count of L-PRP preparation was 899±398 x 106/ml, white blood count was 28±12 x 
106/ml, neutrophils 16.84±9 x 106/ml, monocytes 2.3±0.8 x 106/ml, lymphocytes 8.5±3.6 x 
106/ml, and red cells 3.37±0.9 x 109/ml.  
The average yield of platelets and white cells was 43% and 41% respectively 
With this method, it was possible to obtain an L-PRP preparation that contained a platelet 
count with a minimal enrichment of 4-fold (average 4.26) from the whole blood and a 




differential count of neutrophils 61%, monocytes 8%, and lymphocytes 31%. (Type 2B 
according to Mishra PRP classification, [16]).   
PPP preparations contained a very low concentration of platelets (< 10 x 106/ml) and no 
other cellular components. 
 
Table 3.1. Cellular composition of L-PRP preparation analysed in 8 donors 
 
PRP preparation 
Single-step method:  Low g centrifugation (200 g) of anticoagulated blood for 10 minutes at 
21°C was used. Under this condition, the centrifugation allows the separation of red cells 
PREPARATION PLT-F WBC NEUTR MONOCY LYMPH RBC
L-PRP donor 1 796 37.31 26.39 2.45 7.77 5.33
WB donor 1 224 9.2 6.15 0.8 2.02 4.48
L-PRP donor 2 815 16.17 7.01 1.43 7.3 3.88
WB donor 2 159 6.41 3.79 0.53 193 3.75
L-PRP donor 3 798 37.18 25.97 3.72 6.91 2.42
WB dnor 3 165 9.3 6.66 0.91 1.58 4.75
L-PRP dnor 4 600 19.17 11.8 1.7 5.3 3.68
WB donor 4 209 5.04 3.43 0.32 1.23 6.72
L-PRP donor 5 1770 48.7 27.07 2.81 16.52 2.65
WB donor 5 212 5.61 2.99 0.41 1.93 4.27
L-PRP donor 6 1165 33.27 18.38 3.11 11.25 2.72
WB donor 6 219 6.18 3.59 0.53 1.95 3.9
L-PRP donor 7 715 12.89 4.09 1.84 6.74 3.18
WB donor 7 284 5.9 3.7 0.37 1.68 4.4
L-PRPdonor 8 536 22.45 14.04 1.6 6.58 3.17
WB donor 8 223 9.01 6.04 0.75 2.04 4.46
Whole Blood
Mean 211.8571 7.291429 4.765714 0.601429 1.775714 4.637143
SD 41.88249 1.80959 1.43658 0.22349 0.296921 0.982662
L-PRP
Mean 899.375 28.3925 16.84375 2.3325 8.54625 3.37875
SD 398.6205 12.55281 9.055518 0.825067 3.652607 0.934779




(lower layer) from the remaining whole blood components. The upper layer contains 
platelets and plasma, the desired PRP product. In order to prevent contamination of cells 
present in the lower portion, only the upper 2/3 of this solution was transferred under sterile 
condition into an empty sterile tube (Corning™ Falcon™ 15ml Conical Tubes, sigma-
Aldrich, Saint Louis, USA). The 1/3 of the upper solution and the lower layer were 
discarded. To prevent cellular damage caused by mechanical stress, large bore sterile 
micropipettes were used to harvest the preparation. 120 µl of the preparation was extracted 
and components measured by the Sysmex analyser.  
PRP volume yielded was approximately one-third the initial volume of WB, with an overall 
platelet yield of 64%. With this method, a 2-fold platelet enrichment from the whole blood 
was consistently obtained. (Average PLT-F in whole blood: 211.8±41.8 x 106/ml, PLT-F in 
PRP: 378±57 x 106/ml). Leucocytes and red cells were consistently negligible (Type 4B 
according to Mishra PRP classification, [16]). 
PREPARATION  PLT-F WBC NEUTR MONOCY LYMPH RBC 
PRP donor1 472 0.02 0 0 0 0 
PRP donor 2 314 0.17 0 0 0 0 
PRP donor 3 321 0.1 0 0 0 0 
PRP donor 4 406 0.02 0 0 0 0 
PRP donor 5 406 0.01 0 0 0 0 
PRP donor 6 407 0.02 0 0 0 0 
PRP donor 7 389 0.01 0 0 0 0 
PRP donor 8 314 0.37 0.23 0.04 0.1 0 
Whole Blood 
      Mean  211.8571 7.291429 4.765714 0.60142857 1.775714 4.637143 
SD  41.88249 1.80959 1.43658 0.22348964 0.296921 0.982662 
PRP 
      Mean  378.625 0.09 0.02875 0.005 0.0125 0 
SD 57.07623 0.126717 0.081317 0.01414214 0.035355 0 





Table 3.2. Cellular composition of PRP preparation analysed in 8 donors 
 
Double-step method: Platelet pellet re-suspended in plasma 
This method consists of a first ‘soft’ spin centrifugation, low g centrifugation (200 g) of 
anticoagulated blood for 10 minutes at 21 C.  The obtained supernatant plasma was 
transferred into another sterile tube. In order to prevent platelet aggregation 5 µl of 
Prostaglandin (PGI2, 1 mg/ml Sigma-Aldrich, Saint Louis, USA) was added. A second 
‘high’ speed centrifugation was performed at a high g centrifugation (1000 g) for 10 min. 
The platelet pellet at the bottom of the tube was obtained and re-suspended in a calculated 
volume of double spun plasma to obtain the desired final platelet concentration. 
Double spun plasma preparation: Following blood collection, a portion of whole blood was 
divided in 1.5 ml microtubes (Sarstedt, Nümbrecht, Germany) and centrifuged at 2000 g for 
20 min. The upper layer was further transferred into 1.5 ml microtubes and a second 
centrifugation at 13,000g for 2 min was performed. The obtained supernatant was 
transferred into a Corning™ Falcon™ (Sigma-Aldrich, Saint Louis, USA) 15 ml tube and a 
sample was analysed by Sysmex.  The pellet obtained from the second centrifugation was 
discarded and this double spun plasma was used to adjust platelet concentration.  
With this method, the desired platelet count was obtained.  
The average PLT-F harvested in the L-PRP preparations was 899.4x 106/ml. In order to 
compare PRP and L-PRP preparations with similar concentration of platelets, the desired 
platelet count target was 900 x 106/ml. Leucocytes and red cells were consistently 
negligible. Repeated analysis of the double spun plasma showed the purity of the 




CHAPTER 4.  ANTIMICROBIAL PROPERTIES OF PRP 
PRODUCTS 
 
4.1 Introduction   
Local infections and sepsis related to burn wounds raise great concerns in the management 
of burn patients. In patients with severe burns (where over 40% of the Total Body Surface 
Area is burned) 75% of  mortality is reported to be related to sepsis from infection of 
wounds or other organs and/or inhalation injuries [122, 123]  
Gram-positive bacteria Staphylococcus Aureus [124] and  Gram-negative bacteria, 
Acinetobacter Baumannii [125-127] and  Pseudomonas Aeruginosa [127-129] are the most 
frequent bacteria strains found in burns wounds. It also has been shown that they are the 
most relevant pathogens of biofilms deep in wounds [130, 131]. Several dressings with 
antimicrobial properties are used do prevent or treat wound colonisation and infection [132]. 
The great concern is in regards the emergence of multidrug resistant organisms and the 
difficulty of eradicate bacteria growing in sessile biofilms. There is thus a need to discover 
novel antimicrobial products that can be effective particularly against these resistant strains 
of bacteria [131].  
PRP products have been safely used in clinical setting to encourage wound healing. The 
alluring antimicrobial properties of these biomaterials suggested in published studies, directs 
our study to further investigate the bactericidal effects of these products. The aim of this 
chapter was to evaluate in vitro antimicrobial effects of different platelet-rich plasma 
preparations (with or without leukocytes) against the most frequent, resistant bacteria 







A series of in vitro experiments were conducted to define the efficacy of the biomaterials in 
terms of their ability to control bacteria growth and biofilm formation.  (Appendix A).  
4.2.1 Donors 
The study group comprised 8 healthy volunteers examined between October 2015 and 
August 2016. All donors were free from infection and none had taken any medication during 
the previous two months. From each 50 ml of whole blood was collected. Written informed 
consent for participation in the study was obtained from each donor with the approval of the 
university research ethics committee.  
4.2.2 Preparation of PPP, PRP, L-PRP 
PPP, PRP, and L-PRP were prepared as described in Chapter 3. 
The antimicrobial effect of these biomaterials was tested with and without platelet activation 
prior to use. Different activators have been suggested by different authors, including calcium 
chloride, autologous and bovine thrombin. Calcium chloride is a safe option especially when 
used in a clinical setting as it has been shown that bovine thrombin can cause coagulopathy 
(ref 26,27). Autologus thrombin is another safe and faster alterative compared to calcium 
chloride, particularly relevant if used in clinical setting to minimise time of application. 
Autologus thrombin preparation kits are now available but the drawback compared to 
calcium chloride is the cost.  Therefore, the activator used in our experiments was sterile 
calcium chloride (CaCl2) at a 22.8 mM (3.4mg/mL) concentration [113], which required 20-
30 minutes incubation for clot formation to occur.  
4.2.3 Neutrophil isolation  
Neutrophils were isolated from whole blood using a standard density gradient separation 




conducted under sterile conditions under a laminar flow hood  and the solutions used were 
filter sterilised using a 33mm filter unit (Miller- GP, Sigma-Aldrich, Saint Louis, USA).  2% 
Dextran solution was used to permit separation of buffy coat from red cells. The solution 
was obtained by adding 1g of Dextran T500 (Pharmacosmos AS, Holbæk, Denmark) to a 
filter sterilised 50 ml of 0.9% normal saline (NaCl) solution. In order to create a gradient, 
80% Percoll and 56% Percoll solutions were required. 6 ml of whole blood was collected  
into anticoagulated lithium heparin tubes (BD Vacutainer Tubes, New Jersey, USA) and 
transferred to 50 ml Falcon centrifuge tubes (Corning CentriStar, Sigma-Aldrich, Saint 
Louis, USA). 2% Dextran was added to a ratio of 1ml of 2% Dextran to 6 ml of whole 
blood. Separation of the buffy coat from the red cells occurred over 40 minutes. The buffy 
coat was layered on to the Percoll solution and centrifuged at 110 rpm (Jouan B4i Bench-top 
Centrifuge, Thermo Scientific, Wilmington, DE, USA) for 20 min (no brake). After 
centrifugation, the blood separated into clear bands: from the bottom to the top: red cells, 
isolation media, neutrophils, isolation media, peripheral blood mononuclear cell (PBMC) 
and plasma.  Using a pipette the neutrophils were transferred into a 50 ml Falcon filled with 
50 ml of RPMI 1640 (Sigma-Aldrich, Saint Louis, USA) medium and centrifuged at 1600 
rpm ((Jouan B4i Bench-top Centrifuge, Thermo Scientific, Wilmington, DE, USA) for 10 
min (no brake). After centrifugation neutrophils were resuspended in RPMI 1640. 
Neutrophil count was assessed using haemocytometer and confirmed by automatic count by 
Countess II Automated Cell Counter (Thermo Fisher Scientific, Waltham, USA). Neutrophil 
count was adjusted to a range of values:  0.5x106/ml to 10x106/ml. 






4.2.4 Bacteria stocks and preparation  
The bacterial strains were obtained from the Laboratory T102, Institute of Microbiology and 
Infection, University of Birmingham. As described in table 4.1, the Gram-positive bacteria 
used was Staphylococcus aureus (MSSA_F77), the Gram-negative bacteria were 
Pseudomonas aeruginosa (PS_PA01) and Acinetobacter Baumannii (AB_AYE). 
Study 
identifier Organism Description 




[ATCC_15692] originally isolated 




MPR Clinical Isolate (unique) 
Table 4.1 List of the control and clinical isolates used in this study 
Bead frozen stocks were removed from the freezer and one bead was streaked across the 
surface on an agar plate. The plate was kept in incubator at 37°C overnight. Bacterial liquid 
stock was prepared as for the following protocol: overnight broth of each organism were 
prepared in duplicate by picking with  a loop and inoculating 2-3 fresh colonies into 5 ml of 
LB (lysogeny broth) media in a universal. Additionally, a universal with only broth was 
prepared and used as negative control. Preparations were incubated overnight at 37°C with 
gentle agitation. On the day of the experiment, fresh MH (Mueller Hinton) broth was 
prepared and submitted for autoclaving. (10.5 g of MH broth powder in 500 ml of water). 
The bacterial count was assessed by optical density (OD) at 600 nm using the Jenway 6300 
spectrophotometer (Bibby Scientific, Stone, Staffordshire, UK). The calibration control used 
was 1000 µl MH broth. For the bacterial preparation, 100 µl of culture were added to 900 µl 




following the formula: Actual OD/ desired OD = (OD reading x 10)/0.1 = fold dilution 
needed.  
4.2.5 Positive and negative controls 
Positive controls: P. aeruginosa in sterile water or A. baumannii and S. aureus in MH broth 
were used as positive control. Experiments were performed using at least six technical 
replicates of each isolate.  
Negative controls: Acetic acid (AA) with a concentration of 5% was included as negative 
control. It has been previously reported that AA has an excellent bactericidal effect against 
Gram-negative bacteria [135] and it is effective at preventing biofilm formation at different 
concentration, from 0.31% up to 5% against P. aeruginosa and A. baumannii [105, 135]. In 
the preparation including S. Aureus, Ciprofloxacin solution (40 mg/ml) was used as negative 
control (10 ml of Ciprofloxacin 40 µg/ml, 0.1 g Ciprofloxacin powder, 1 ml 5% AA, 9 ml 
sterile water).  Hanks' Balanced Salt Solution (HSSB), MH broth, sterile water was also used 
as negative controls.  
4.2.6 Antimicrobial activity assay  
The antimicrobial activity of blood  preparations was tested using the Kirby-Bauer disc- 
diffusion method, a growth kinetic assay and a crystal violet biofilm formation assay.  
Kirby-Bauer disk diffusion  
The antimicrobial activity of blood preparations was tested using the Kirby-Bauer disc- 
diffusion method [136]. Lysogeny Broth (LB) agar plates were coated with methicillin-
sensitive S. Aureus MSSA_F77 and P. Aeruginosa PS_PA01.  75 µl of PPP, L-PRP, and 
PRP, all previously activated with CaCl2 (solution of 180 µl + 20 µl CaCl2) were coated in 




previously activated with CaCl2 (solution of 180 µl + 20 µl CaCl2) were coated in the 
MSSA_F77 plate.  Ciprofloxacin (40 mg/ml) was used as negative control.   
The agar plates were incubated at 37˚C and the antimicrobial activity was visually assessed 
after 18- 24 hours by measuring the zones of inhibition. Biomaterials were considered to 
exhibit antimicrobial properties if a zone of growth inhibition is observed and recorded as 
the diameter in millimetres across the centre of the coated discs.  
Growth kinetics assay 
The growth kinetics of all strains were determined by measuring the optical density (OD) of 
cultures automatically in a FLUOstar Optima (BMG LABTECH, UK), as previously 
described [137]. The growth kinetics of all cultured biomaterials and controls included in a 
96-well plate were examined by determining optical density (OD) using a 
spectrophotometer.  Growth data were obtained in 8 different donors, 3 different bacteria 
strains, and each containing a minimum of four technical replicates. The rate of growth was 
analysed over a 12 h and 20 min period at 37°C. The FLUOstar instrument settings are listed 
in table 4.2.  Increases in the optical density readings over time are caused by increased 
turbidity indicating bacterial growth. The line graph (figure 4.1) illustrates a typical change 
in OD of both positive and negative controls over 12 hours In the preparation including 
MSSA_F77 and broth (positive control) OD increased over time as expected from the 
increased turbidity of the preparation. The OD in the preparation with Ciprofloxacin 






Figure 4.1 Growth kinetics of MSSA_F77 and negative control assessed by optical density 
 
Modality Absorbance - Growth 
Time 12 h 20 min 
Excitation filter 600 nm 
Emission filter 600nm 
Numb circle 75 
Shaking time before each 
circle 
4 sec 
Table 4.2 FLUOstar OPTIMA settings for GK 
 
Growth Kinetics: MSSA_F77 spiking  
In order to evaluate the antimicrobial effects of PPP, PRP and L-PRP and isolated 
neutrophils against MSSA_F77, a 96-well MTT [Corning, New York] was seeded as for the 
following protocol: 
For each donor a total volume of 1ml of PPP, PRP, L-PRP and isolated neutrophils was 
required.1ml of each preparation contained:  
100 µl of biomaterial [primed/un-primed isolated neutrophils, activated PPP/PRP/L-PRP (10 
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  1 2 3 4 5 6 7       8          9         10    11          12 
A PPP PPP PPP 
B L-PRP L-PRP L-PRP 
C PRP PRP PRP 
D Neutrophils (primed) Neutrophils (primed) Neutrophils (primed) 
E Neutrophils (unprimed) Neutrophils (unprimed) Neutrophils (unprimed) 
F POS (MHB+MSSA_F77) POS (MHB+MSSA_F77) POS (MHB+MSSA_F77) 
G Control (Cipro) Control (Cipro) Control (Cipro) 
H Control (MHB) Control (MHB) Control (MHB) 
 DONOR 1 DONOR 2 DONOR 3 
Table 4.3 Growth Kinetics: MSSA_F77. Sample of designed template for 96-well MTT 
 
Growth Kinetics: AB_AYE and PA01_PA01 spiking  
To evaluate the antimicrobial effects of PPP, PRP, L-PRP and isolated neutrophils against 
AB_AYE and PA01_PA01, a 96-well MTT [Corning, New York] was seeded as for the 
following protocol: In each well of a 96-well MTT, 100µl of the AB_AYE or PA01_PA01 
and 100µl of PPP, L-PRP or PRP preparations were seeded (table 4.4). 
  1 2 3 4 5 6 7 8 9 10 11 12 
 
A 
100 μl PPP + 100 μl AYE 100 μl PPP + 100 μl AYE 
 
B 
100 μl PRP + 100 μl AYE 100 μl PRP + 100 μl AYE 
AYE C 
100 μl AYE+ 100 μl MHB  100 μl AYE+ 100 μl MHB  
 
D 
100 μl AA+ 100 μl AYE 100 μl AA+ 100 μl AYE 
 
E 
100 μl PPP + 100 μl PA01 100 μl PPP + 100 μl PA01 
 
F 
100 μl PRP + 100 μl PA01 100 μl PRP + 100 μl PA01 
PA01 G 
100 μl AYE+ 100 μl WATER 100 μl AYE+ 100 μl WATER 
 H 
100 μl AA+ 100 μl PA01 100 μl AA+ 100 μl PA01 
 
DONOR 1 DONOR 2 
 






Biofilm formation and detection 
The ability of the biomaterials to prevent biofilm formation was evaluated using a crystal 
violet biofilm formation assay as described by Baugh et al. [138]. The following bacteria 
strains have been tested: 
• PS_PA01 Pseudomonas aeruginosa ATCC_15692 (10,2,2/4,2/5,5,3,3,8) 
• PS_919 Pseudomonas aeruginosa QEHB Clinical burn isolate (10,2,5,4,6,2,-,4) 
• AB_AYE Acinetobacter baumannii MPR Clinical Isolate (unique) 
• AB_53 Acinetobacter baumannii QEHB Clinical burn isolate (QUEE13AC-27) 
The ability of biofilm production of S. aureus has been previously studied by our group 
[105] and demonstrated  that biofilm production was both poor and unreliable.  
In each well of a 96-well MTT [Corning, New York], 100 µl of the test strains and 100µl of 
PPP, L-PRP or PRP were seeded. Suitable controls were included in each assay. Negative 
controls were: 200 µl of MH broth and 100 µl of the test strains and 100 µl of 5% AA. 
Positive controls were: 100µl AB_AYE in 100 µl of MH broth and 100 µl PS_PA01 in 100 
µl of sterile water (table 4.5). Plates were sealed and statically incubated at (37°C) for 3 
hours allowing biofilm formation. The liquid was removed from the wells and thoroughly 
the plates were rinsed in tap water in order to remove any unbound cells. Existing formed 
biofilms were visualised through staining with 1% crystal violet (CV) [Sigma Aldrich, 
Poole, UK] solution for 15 minutes and subsequently rinsed with tap water to remove any 
unbound CV. The bound dye was then solubilised by the addition of 70% ethanol. After 15 
minutes incubation the biomass of the biofilm of the solubilised CV solution was measured 
using a FLUOstar Optima [BMG Labtech]. All biofilm assays were performed twice with 





  1 2 3 4 5 6 7 8 9 10 11 12 
A 
L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP L-PRP 
B 
PRP PRP PRP PRP PRP PRP PRP PRP PRP PRP PRP PRP 
C 
PPP PPP PPP PPP PPP PPP PPP PPP PPP PPP PPP PPP 
D 





   
E 





   
F 





   
G AA AA AA AA AA AA AA AA AA AA AA AA 
H 
POS (in broth) 
POS(in water) 
                           AB-AYE         PS_PA01   
Table 4.5 Biofilm formation. Sample of 96-well MTT seeded with PPP, L-PRP, PRP 
products and controls 
 
4.2.7 Statistical analysis 
Kinetics Analysis: The kinetics were modelled over time using linear mixed models that can 
account for the variability in measurements between donors and the repeated measures 
structure of the data. Models incorporating three different random effects structures were 
explored and we found that the model that included both random slopes and intercepts with 
no correlation between them provided the best fit to the data, as measured using AIC 
(Akaike information criterion). We allowed the time of the observation to be modelled using 
a restricted cubic spline to allow for flexible non-linear models to be fit to the data.  The 
number of knots in the spline was determined using AIC. ANOVA was used to assess the 





Biofilm analysis: Preliminary tests of the biofilm forming ability of different bacteria were 
studied using Kruskal-Wallis tests (section 4.3.3). Poor biofilm forming bacteria were 
excluded for further analysis. The effect of group on the biomass level for selected bacteria 
was then assessed using one-way analysis of variance (ANOVA) (section 4.3.4).  Visual 
inspection and descriptive summaries of the data suggested that the groups exhibited 
different means and standard deviations.  Levene’s test was used to formally assess the 
equality of variances across the groups and Welch’s statistic provided a robust test of 
equality of means corrected for heteroscedasticity. Games-Howell adjustments were used to 
account for the unequal variances in the post-hoc tests of mean differences between groups.  
Statistically significance was assessed using a threshold of p<0.05. All analysis was 





4.3 Results  
4.3.1 Kirby-Bauer disk diffusion   
PPP, L-PRP, PRP preparations all failed to show any MSSA_F77 growth inhibition. (Figure 
4.2). After 18 hours incubation, no inhibition zone was detected in the plates where the 
biomaterials were inoculated. As expected a large zone of inhibition was observed with the 
MSSA_F77 coated plate in the presence of Ciprofloxacin. An undefined inhibition zone was 
observed for the PS_PA01 coated plate in the presence of activated L-PRP after 18 hours 
incubation (figure 4.3). 
  
Time of L-PRP inoculation  18 hours incubation  




Time of L-PRP inoculation  12 hours incubation  





4.3.2 Bacteria growth after 24 h incubation  
All the preparations were further incubated overnight at 37˚C and inspected the next day to 
visually assess the turbidity (figure 4.4).  PPP, PRP, L-PRP, isolated neutrophils inoculated 
with MSSA_F77, AB_AYE, PS_PA01 and positive control were turbid. Negative controls 
remain clear after 24 hours. 
 
Figure 4.4 Visual assessment of turbidity of the preparation  
4.3.3 Bacteria ability to form biofilm  
A spectrum of biofilm formation was consistently seen for PS_PA01 and AB_AYE and 
therefore included in the study for the further analysis of anti-biofilm effects of blood 
products (figure 4.5). PS_919 and AB_53 were poor at producing biofilms. Isolates where 
the average biofilm formation (as measured by OD) after crystal violet staining was not 
significantly different to the broth or controls, were excluded from further analysis. In figure 
4.4, the optical density on the y axis refers to the average biofilm biomass for all the isolates 
shown on the x axis. It is apparent that AB_53 and PS_919 demonstrated poor ability to 
form biofilms ability when compared to their other species counterparts. Using Kruskal-




compared. In contrast, PS_PA01 and AB_AYE showed excellent biofilming capability 
compared to theirs controls (p-value <0.001).   
 
Figure 4.5. Biomass of the biofilms produced by the isolates tested.  
Optical density on the y axis refers to the mean biofilm biomass for all the isolates shown on 
the x axis.  Error bars: standard error of the mean for each value. *: values statistically 
significantly different between the 3 groups (p-value<0.001). (n):  numbers of replicates for 
each isolate tested  
 
4.3.4 Effects of Blood Products in preventing biofilm formation   
Blood was drawn from 2 healthy donors and blood products were prepared as described in 
Chapter 3.2.4. The composition of blood products for each donor is shown in table 4.6. In 
donor 1, in the L-PRP preparation PLT-F was 4-fold increase from the whole blood, WBC 
3.9-fold, neutrophils 3.3-fold, lymphocytes 4.6-fold, and monocytes 3.3-fold and red cell 
count similar to whole blood.  In the PRP preparation, using the double spin method, PLT-F 
was 3.8-fold increased than whole blood.  
In donor 2, in the L-PRP preparation PLT-F was 4.4-fold increase from the whole blood, 




cell count was decreased from whole blood by 2-fold.  In the PRP preparation, using the 
double spin method, PLT-F was 4.3-fold increased than whole blood. 
 
 PLT-F WBC RBC 
DONOR 1  





 4.37 x109/ml 






PRP 889x106/ml 0 0 
DONOR 2 









PRP 890x106/ml 0 0 
Table 4.6 Platelets and Leucocytes composition in different Blood-Derived products 
 
Different blood preparations such as activated L-PRP, non-activated L-PRP, PPP, PRP, 
negative control (PA01 + 5% AA and broth) and positive control (PA01 + water) were 
tested against Pseudomonas Aeruginosa PS_PA01 and Acinetobacter Baumannii AB_AYE. 







Analysis of Donor 1 
Pseudomonas Aeruginosa PS_PA01 
The observed data for each group are plotted (figure 4.6). For each group, data of the 6 
replicates are plotted.  
 
Figure 4.6 Donor 1 PS_PA01 biomass reading 
The plot clearly shows that the levels of biofilm mass (expressed as levels of absorbance) 
were minimal in the following preparations:  
- Preparations including PS_PA01+activated LPRP, PS_PA01+no activated LPRP, 
PS_PA01+PRP, and PS_PA01+PPP.  
- Negative controls: sterile water, and PS_PA01+ 5% Acetic Acid.  
Positive control (PS_PA01+Water group) had elevated levels of biofilm biomass relative to 




A test of homogeneity of variances returns a Levene’s test statistic of 15.347 (6,35 degrees 
of freedom; p-value: <0.001) suggesting there is strong evidence in our data to reject the 
assumption of equal variances. Accounting for the unequal variances, an ANOVA using 
Welch’s robust test of equality of means returns a statistic of 44.71 (6, 14.991 degrees of 
freedom; p-value: <0.001) giving convincing evidence for statistically significant mean 
differences between groups. Post-hoc tests of mean differences between groups are carried 
out using Games-Howell adjustments, and we find the following pairs with a statistically 
significant difference in means using a threshold of p<0.05 (Table 4.7): 











PA01 + water  
activated 
LPRP 
0.468 0.042 0.000 0.287 0.648 
PA01 + water  
no activated 
LPRP 
0.576 0.041 0.000 0.392 0.760 
PA01 + water  PPP 0.554 0.041 0.000 0.370 0.737 
PA01 + water PA01 + 5%AA 0.550 0.042 0.000 0.367 0.732 
PA01 + water broth 0.571 0.041 0.000 0.387 0.754 





0.109 0.011 0.001 0.062 0.155 
activated 
LPRP 
PPP 0.086 0.011 0.002 0.040 0.132 
activated 
LPRP 
PA01 + 5%AA 0.082 0.012 0.002 0.036 0.128 
activated 
LPRP 
broth 0.103 0.011 0.001 0.057 0.149 
activated 
LPRP 




0.023 0.004 0.003 0.009 0.036 
PPP broth 0.017 0.005 0.043 0.000 0.034 






Acinetobacter baumanii AB_AYE  
The observed data for each group are plotted (figure 4.7). For each group, data of the 6 
replicates are plotted.  
 
Figure 4.7 Donor 1 AB_AYE biomass reading 
The plot clearly shows that the levels of biofilm mass (expressed as levels of absorbance) 
were minimal in the following preparations:  
- Preparations including AB_AYE+activated LPRP, AB_AYE +no activated LPRP, 
AB_AYE +PRP, and AB_AYE +PPP.  
- Negative controls: broth, and AB_AYE + 5% Acetic Acid.  
Positive control group (AB_AYE + broth) had elevated levels of biofilm biomass relative to 
the other groups suggesting a significant effect of all preparations on bacterial growth. 
A test of homogeneity of variances returns a Levene’s test statistic of 20.865 (6,84 degrees 




the assumption of equal variances. Accounting for the unequal variances, an ANOVA using 
Welch’s robust test of equality of means returns a statistic of 70.80 (6, 23.288 degrees of 
freedom; p-value: <0.001) giving robust evidence for statistically significant mean 
differences between groups. Post-hoc tests of mean differences between groups are carried 
out using Games-Howell adjustments and we find the following pairs with a statistically 
significant difference in means using a threshold of p<0.05 (Table 4.8): 











AYE + broth  activated LPRP 0.357 0.020 0.000 0.288 0.426 
AYE + broth  
no activated 
LPRP 0.361 0.021 0.000 0.291 0.432 
AYE + broth  PRP 0.353 0.020 0.000 0.284 0.422 
AYE + broth PPP 0.315 0.020 0.000 0.245 0.384 
AYE + broth AYE+ 5%AA 0.311 0.019 0.000 0.243 0.378 
AYE + broth broth 0.352 0.019 0.000 0.285 0.420 
activated LPRP PPP -0.042 0.010 0.006 -0.074 -0.010 
activated LPRP AYE+ 5%AA -0.046 0.006 0.002 -0.071 -0.021 
no activated 
LPRP PPP -0.047 0.011 0.008 -0.083 -0.010 
no activated 
LPRP AYE+ 5%AA -0.051 0.009 0.002 -0.082 -0.020 
PRP PPP -0.038 0.010 0.022 -0.072 -0.004 
PRP AYE+ 5%AA -0.042 0.007 0.007 -0.071 -0.014 
PPP broth 0.038 0.008 0.005 0.010 0.065 





Analysis of Donor 2 
Pseudomonas Aeruginosa PS_PA01 
The observed data for each group are plotted (figure 4.8). For each group, data of the 6 
replicates are plotted.  
 
Figure 4.8 Donor 2 PS_PA01 biomass reading 
 
Positive control (PS_PA01+Water group) had elevated levels of biofilm biomass relative to 
the other groups with a wider range of values than seen for donor 1, though an effect of all 
preparations was again suggested. The large variability in the observed values meant there 
were no statistically significant differences between the mean absorbance value of the 
positive control (PS_PA01+Water group) and the other groups. 
A test of homogeneity of variances returns a Levene’s test statistic of 19.912 (6,35 degrees 




assumption of equal variances. Accounting for the unequal variances, an ANOVA using 
Welch’s robust test of equality of means returns a statistic of 18.670 (6, 15.259 degrees of 
freedom; p-value: <0.001) giving robust evidence for statistically significant mean 
differences between groups. Post-hoc tests of mean differences between groups are carried 
out using Games-Howell adjustments and we find the following pairs with a statistically 
significant difference in means using a threshold of p<0.05 (Table 4.9): 
 











activated LPRP PPP -0.159 0.034 0.027 -0.298 -0.019 
no activated 
LPRP 
PPP -0.097 0.022 0.019 -0.178 -0.015 
PPP PA01 + 
5%AA 
0.143 0.020 0.001 0.069 0.217 
PPP broth 0.146 0.015 0.000 0.090 0.201 
PA01 + 5%AA PRP -0.102 0.021 0.008 -0.177 -0.027 
broth PRP -0.104 0.016 0.001 -0.162 -0.046 







Acinetobacter baumanii AB_AYE 
 
The observed data for each group are plotted (figure 4.9). For each group, data of the 6 
replicates are plotted.  
 
Figure 4.9 Donor AB_AYE biomass reading 
Positive control group (AB_AYE + broth) had elevated levels of biofilm biomass relative to 
the other groups, suggesting and inhibitory effect of the various preparations on bacterial 
growth.  
A test of homogeneity of variances returns a Levene’s test statistic of 2.638 (6,51 degrees of 
freedom; p-value: 0.026) suggesting there is strong evidence in our data to reject the 
assumption of equal variances. Accounting for the unequal variances, an ANOVA using 
Welch’s robust test of equality of means returns a statistic of 10.626 (6, 19.744 degrees of 
freedom; p-value: <0.001) giving strong evidence for statistically significant mean 




out using Games-Howell adjustments and we find the following pairs with a statistically 
significant difference in means using a threshold of p<0.05 (Table 1.10): 
 











AYE + broth activated LPRP 0.284 0.035 0.000 0.153 0.414 
AYE + broth  
no activated 
LPRP 
-0.273 0.035 0.000 0.143 0.404 
AYE + broth  PRP  -0.273 0.038 0.000 0.139 0.408 
AYE + broth   PPP  -0.308 0.080 0.045 0.007 0.609 
AYE + broth AYE+ 5%AA 0.309 0.037 0.000 0.176 0.443 
AYE + broth broth 0.263 0.040 0.000 0.126 0.401 




4.3.5 Growth kinetic essay  
Acinetobacter baumanii AB_AYE 
Bacterial growth (expressed as absorbance) over 12 hours and 20 min for the 8 donors is 
shown in figure 4.10.  The dashed line corresponds to the control samples.  For each donor, 
separate lines for PPP and PRP are displayed. 
Figure 4.10 AB_AYE growth (expressed as absorbance) over time plotted for the 8 donors 
 
The level of absorbance was different at time 0 for the four different groups (PPP, PRP, AA, 
and control) and changed over time with different kinetics for each preparation varied by 
time. Some donor preparations clearly inhibited growth compared to the control (PPP for 
donors 1, 2, and 6) whereas others showed little effect of the PRP from donors 1, 4, and 5). 
Figure 4.11 shows the model fitted values of absorbance for the four groups over time using 





Figure 4.11 AB_AYE growth over time. Model fitted values of absorbance for the AA, 
Control, PPP and PRP groups  
 
Interested in the relative change over time, rather than the absolute change, we scaled the 
data so that the absorbance at time 0 for each donor and control was scaled to 0.             
The ‘Group’ main effect is now effectively zero, but the main effect of time and the 
interaction between time and group are both statistically significant.  The model fitted output 





Figure 4.12 AB_AYE growth over time. The absorbance at time 0 for each donor and control 
is scaled to 0  
 
There is now a clear difference in the behaviour of the Control sample over time compared 
with the other three groups and all three test groups showed lower absorbance than the 
control group.  There is little difference between the PPP and PRP groups by the end of the 
experiment.  Although the AA group is not distinguishable from the PPP group, this is likely 
to be a result of insufficient data to provide a suitably precise estimate of the absorbance in 
the AA group over time.  We can observe this by examining the estimated levels of 
absorbance at 0 hours and at 12 hours 20 minutes.  These estimates are presented, along with 
95% CIs, in the following table:  
Group Time = 0 minutes Time =12hrs 20 minutes 
 Est 95%CI Est 95%CI 
AA 0.002 (-0.049, 0.053) 0.020 (-0.146, 0.187) 
Control -0.037 (-0.088, 0.014) 0.876 (0.709, 1.042) 
PPP -0.062 (-0.098, -0.026) 0.302 (0.184, 0.419) 





When the control group is compared to the PPP group, the p-value of the interaction term is 
<0.0001, suggesting there is a highly statistically significant difference between the groups.  
Similarly, comparing the control group to the PRP group, the p-value for the interaction 
term is <0.0001.  
Analysing the data at 12h and 20 min post incubation using pairwise tests comparing each 
group with all the others, we can see that PPP and PRP preparation are both significantly 
different to control group (p-value <0.0001) whilst there is no significant difference between 
the 2 preparations and the preparation including AB_AYE+5%Acid Acid.  
Therefore, we can state that the preparations including AB_AYE+5%Acid Acid (negative 
control), AB_AYE+PRP, and AB_AYE+PPP significantly reduced AB_AYE growth 
compared to the positive control (AB_AYE+broth), overtime and 12 hours post incubation.  
Group 1  Group 2 p-value 
AA CONTROL <0.0001 
AA PPP 0.0078 
AA PRP 0.0241 
CONTROL PPP <0.0001 
CONTROL PRP <0.0001 







Pseudomonas Aeruginosa PS_PA01 
The absorbance over time for the 8 donors is plotted in figure 4.13.  The dashed lines 
correspond to the control samples.  For each donor, separate lines corresponding to PPP and 
PRP are displayed. 
 
Figure 4.13 PS_PA01 (expressed as absorbance) over time plotted for the 8 donors 
 
The level of absorbance was again different at time 0 for the four distinct groups (PPP, PRP, 
AA and control), varied by time and did so in a different manner depending on the group.  





Figure 4.14 PS_PA01 growth over time. Model fitted values of absorbance for the AA, 
Control, PPP and PRP groups 
 
To obtain a clearer estimate of the relative changes over time by group, data were scaled so 
that the absorbance at time 0 for each donor and control is scaled to 0.  
The ‘Group’ main effect is now effectively zero, but the main effect of time and the 
interaction between time and group are both statistically significant.  The model fitted output 






Figure 4.15 PS_PA01 growth over time. The absorbance at time 0 for each donor and control 
is scaled to 0 
 
We now see a clear difference in the behaviour of the control sample over time compared 
with the other three groups and the PPP and PRP were similarly effective.   
As for the AYE analysis, we now see a clear difference in the behaviour of the Control 
sample over time compared with the other three groups.  There is little difference between 
the PPP and PRP groups by the end of the experiment, although the trajectories of the lines 
do suggest potential divergence were the experiment to be run for a longer period of time.  
Again, the AA group is not distinguishable from the PPP or PRP groups and this is likely to 
be a result of insufficient data to provide a suitably precise estimate of the absorbance in the 




at 0 hours and at 12 hours 20 minutes.  These estimates are presented, along with 95% CIs, 
in the following table:  
Group Time = 0 minutes Time =12hrs 20 minutes 
 Est 95%CI Est 95%CI 
AA 0.005 (-0.072, 0.082) 0.044 (-0.119, 0.207) 
Control -0.104 (-0.181, -0.027) 0.641 (0.478, 0.804) 
PPP -0.038 (-0.092, 0.016) 0.213 (0.098, 0.328) 
PRP -0.017 (-0.072, 0.037) 0.142 (0.027, 0.258) 
 
The interaction terms between the control group and both the PPP and PRP group are 
statistically significant, suggesting there is a difference between the groups over time. 
When the control group is compared to the PPP group, the p-value of the interaction term is 
<0.0001, suggesting there is a highly statistically significant difference between the groups.  
Similarly, comparing the control group to the PRP group, the p-value for the interaction 
term is <0.0001.  
Analysing the data at 12h and 20 min post incubation using pairwise tests comparing each 
group with all the others, we can see that PPP and PRP preparation are both significantly 
different to control group (Control versus PPP: p-value <0.0001 and Control versus PRP: p-
value: 0.027) whilst there is no significant difference between the 2 preparation and the 
preparation including PA_01+5%Acid Acid.  
Group 1 Group 2 p-value 
AA CONTROL <0.0001 
AA PPP 0.0042 
AA PRP 0.4463 
CONTROL PPP <0.0001 
CONTROL PRP 0.0027 






Therefore, we can state that the preparations including PA_01+5%Acid Acid (negative 
control), PA_01+PRP, and PA_01+PPP significantly reduced PA_01 growth compared to 
the positive control (PA_01+broth), overtime and 12 hours post incubation.  
Effect of removing PA01 Donor 3 removed 
The behaviour in the PRP measurements for donor 3 (D3) was noticeably different from 
other preparations and thus we re-ran the above analysis on the data with D3 removed. 
However, we obtained a similar result to the previous analyses (data not shown) and thus 
these data remained in the analysis.   
Staphylococcus aureus MSSA_F77  
 
The absorbance over time for the 8 donors is plotted in figure 4.16.  The dashed lines 
correspond to the control samples (CIPRO stands for Ciprofloxacin and POS for Positive 
control, F77 in broth). 
 




All three model terms - main effect of time, main effect of group, and the interaction 
between group and time - were statistically significant, but the main effect of group was not.  
From this we can infer that the level of absorbance was different between the five different 
groups (CIPRO, Control, PRP, L-PRP, and PPP) at time 0.  Figure 4.17 shows quite clearly 
that the values of L-PRP are considerably higher than for any other group over all time 
points and that none of the other treatments with the exception of ciprofloxacin differed 
from the control.  
 
Figure 4.17 MSSA_F77 growth over time. Model fitted values of absorbance for the 
Ciprofloxacin, Control, PPP, PRP and L-PRP groups 
Interested in the relative change over time, rather than the absolute change, we scaled the 
data so that the absorbance at time 0 for each donor and control is scaled to 0. The model 




We can examine the estimated levels of absorbance at 0 hours and at 12 hours 20 minutes.  
These estimates are presented, along with 95% CIs, in the following table:  
Group Time = 0 minutes Time =12hrs 20 minutes 
 Est 95%CI Est 95%CI 
CIPRO 0.002 (-0.103, 0.107) 0.052 (-0.094, 0.197) 
L-PRP 0.080 (0.006, 0.154) -0.085 (-0.188, 0.018) 
POS -0.042 (-0.147, 0.063) 0.953 (0.808, 1.099) 
PPP -0.046 (-0.124, 0.031) 0.685 (0.579, 0.790) 
PRP -0.050 (-0.124, 0.024) 0.757 (0.655, 0.860) 
 
If we compare the CIPRO group to the PPP group, the p-value of the interaction term is 
<0.0001, suggesting there is a highly statistically significant difference between the groups.  
Similarly, comparing the POS group to the PPP group, the p-value for the interaction term is 
<0.0001. There is a large degree of overlap between the groups by 12 hours 20 minutes with 
no evidence in the data to distinguish between the three groups at that time.  The trajectories 
of all three groups are different, but the lack of precision around the estimated absorbance 
means that we cannot conclude that there are significant differences between the groups.  
Looking at predicted averages alone, there is only a 0.3 unit difference between the 





Figure 4.18 MSSA_F77 growth over time. The absorbance at time 0 for each donor and 
control is scaled to 0 
 
In these adjusted data, whilst PRP and PPP preparations did not show growth control of 
MSSA_F77, whilst the preparation including leucocytes (L-PRP) does have a major effect 
on bacterial growth, being able to control MSSA_F77 growth and being significantly 
different to control at 12 hours post incubation (p- value <0.0001).  
Group 1 Group 2 p-value 
CIPRO CONTROL <0.0001 
CIPRO L-PRP <0.0001 
CIPRO PPP 0.0026 
CIPRO PRP <0.0001 
CONTROL L-PRP <0.0001 
CONTROL PPP 0.1537 
CONTROL PRP 0.1126 
L-PRP PPP <0.0001 
L-PRP PRP <0.0001 






L-PRP Data Adjusted for Covariates 
Each donor gave a different baseline blood count, thus leading to different platelet and white 
blood cell counts, in the final L-PRP preparation, as reported in Chapter 3, table 3.1. The 
value of platelets, WBC, neutrophils, monocytes, and lymphocytes are expressed as 106/ml. 
We considered each potential covariate in turn as we did not have sufficient data to include 
them all in one model.  The following analyses should be regarded as exploratory due to the 
limited amount of data available on the covariates in the model. As in the previous analyses 
we allowed the time of the observation to be modelled using a restricted cubic spline to 
allow for flexible non-linear models to be fit to the data. 
Platelets (PLT): We fitted a model including Platelets and Time both as main effects and as 
an interaction term. The best fitting model produced the output reported in figure 4.19.  
 





This suggests that the higher the value of PLT, the higher the initial (t=0) and final (t = 12 
hours 20 minutes) levels of absorbance.  There are statistically significant main effects of 
time (p=0.0004) and PLT (p=0.0002) but no significant interaction term (p=0.72), 
suggesting that the value of PLT does not affect the trajectory of absorbance over time. 
 
White Blood Count (WBC): We fitted a model including WBC and time both as main 
effects and as an interaction term.  The best fitting model produced the output reported in 
figure 4.20.  
 
Figure 4.20 MSSA_F77 growth over time. L-PRP group adjusted modelling for WBC value 
 
There are statistically significant main effects of time (p=0.0003) and WBC (p=0.0003) and 




trajectory of absorbance over time.  The fitted model output suggests that a higher WBC 
value results in a greater dip in absorbance by 4 hours before returning to a value by the end 
of the experiment that is reduced relative to the initial values. 
Neutrophils: We fitted a model including neutrophils (NEUTR) and time both as main 
effects and as an interaction term.  The best fitting model produced the output reported in 
figure 4.21.  
 
Figure 4.21 MSSA_F77 growth over time. L-PRP group adjusted modelling for neutrophils 
value 
 
There are statistically significant main effects of time (p=0.0001) and neutrophil value 
(p<0.0001) and a significant interaction term (p<0.0001), suggesting that the value of 
neutrophils does affect the trajectory of absorbance over time.  The fitted model output 




There is considerable separation in the trajectories for the three values of neutrophils, 
suggesting that the trajectories are quite sensitive to the recorded neutrophil value. 
Monocytes: We fitted a model including monocyte and time both as main effects and as an 
interaction term.  The best fitting model produced the output reported in figure 4.22.  
 
Figure 4.22 MSSA_F77 growth over time. L-PRP group adjusted modelling for monocytes 
value 
 
We find that the higher the monocyte value, the higher the initial (t=0) and final (t = 12 
hours 20 minutes) levels of absorbance.  There are statistically significant main effects of 
time (p=0.0004) and monocyte level (p=0.0004) but no significant interaction term (p=0.33), 




Lymphocytes: We fitted a model including lymphocyte and time both as main effects and 
as an interaction term.  The best fitting model produced the output reported in figure 4.23.  
 
Figure 4.23 MSSA_F77 growth over time. L-PRP group adjusted modelling for 
lymphocytes value 
 
We find that the higher the lymphocyte value, the higher the initial (t=0) and final (t = 12 
hours 20 minutes) levels of absorbance. For a given lymphocyte value the initial and final 
absorbance values also seem similar, although there is considerable uncertainty associated 
with these estimated values. There are statistically significant main effects of time 
(p=0.0004) and lymphocyte level (p=0.0002) but no significant interaction term (p=0.73), 






Isolated Neutrophils   
The absorbance over time for the different concentrations of isolated neutrophils tested is 
plotted below (figure 4.24).  The dashed lines correspond to the control samples (POS, as 
Positive control indicating the preparation including MSSA_F77 in broth and CIPRO, 
indicating the preparation including MSSA_F77 and ciprofloxacin) and are the same in each 
panel. 
 
Figure 4.24 MSSA_F77 (expressed as absorbance) over time plotted for different 
concentration of isolated neutrophils 
Overall, the plot clearly shows that preparation with isolated neutrophils do not have 
bacterial growth control. Primed neutrophils at the 2x106/mls concentration were tested, a 
great bacterial control was detected. This data has not been further confirmed in repeated 




CHAPTER 5. DISCUSSION 
 
The antimicrobial property of PRP preparations is unquestionably an attractive addition to 
the known wound healing effect of these biological blood-derived products. From the 
literature research, we established that although the inclusion of leucocytes in PRP 
preparations was previously neglected and few studies have been conducted to assess the 
specific antimicrobial contribution of the leucocytes. The limited numbers of studies so far 
conducted, the lack of standardisation of the methodology of blood-derived products’ 
preparation, and the wide variability of comparators evaluated did not provide enough 
evidence to determine the specific contribution of leucocytes to the bactericidal effect of 
PRP preparation. However, overall PRP preparations, whether containing or excluding 
leucocytes demonstrated bacteriostatic properties against the majority of the bacterial strains 
tested. 
With the intention of testing either wound healing or bactericidal properties of PRP 
products, it is crucial to firstly standardise the methodology of PRP preparations, showing 
the ability to reproduce consistent results in the preparation of the biomaterials.  Therefore, 
the first part of our experimental study was dedicated to the standardisation of the 
methodology of the preparation of PRP.  
Araki et al. [139] had previously demonstrated that a maximum platelet yield using low g 
for 10 minutes can be obtained using this a single low spin step method. This methodology, 
is the standard method used in our laboratory to obtain PRP and allows to obtain a PRP 
product that consistently yields 2-fold platelet enrichment from the whole blood, with 




[16]. The PRP product obtained with this method has been used to test the antimicrobial 
properties of the blood product against Gram positive bacteria (MSSA F_77).  
For all our experiments, PPP and L-PRP preparations were obtained using a single high-
speed method, which allows to obtain a L-PRP product with a platelets concentration with 
minimal 4-fold enrichment from whole blood, and a minimal leucocyte count with a 
minimal enrichment of 3-fold (Type 2B according to Mishra PRP classification [16].  
As with the L-PRP, the PRP preparation that included leucocytes, we could reach a higher 
concentration of platelets (4-fold enrichment from whole blood), with the progression of our 
study, we decided to aim to a higher concentration of platelets included in our PRP 
preparation [11] with a minimal 4-fold platelet enrichment from the whole blood (still Type 
4B according to Mishra PRP classification [16].  Therefore, when Gram negative bacteria 
(Acinetobacter Baumannii and Pseudomonas Aeruginosa) were tested, we adopted the 
double-step method for PRP production. Our research aim was to test if PRP products have 
an effect on controlling bacteria growth and/or prevent biofilm formation. We chose to 
evaluate the antibacterial effect of these biomaterials against two Gram-negative bacteria (P. 
aeruginosa and A. Baumanii) and one Gram-positive bacteria (S. aureus) as these pathogens 
have been shown to be significant contributors to the delay of wound healing and relevant 
biofilm producers [105, 140, 141]. 
In summary, our present study revealed some interesting preliminary findings: 
▪ The preparation that only includes isolated neutrophils did not inhibit bacterial 
growth for MSSA_F77; 
▪ PRP and PPP preparations reduced AB_AYE and PS_PA01 bacterial growth; 




▪ L-PRP preparation was able to control MSSA_F77 growth.  
▪ PRP, PPP, and L-PRP preparations prevented both AB_AYE and PS_PA01 biofilm 
formation. 
To the best of our knowledge, this is the first study assessing the ability of blood products to 
prevent biofilm formation against P. aeruginosa and A. baumannii. 
Interestingly, our findings show that all the biomaterials tested had the ability to reduce 
levels of biofilm biomass.  
Against P. aeruginosa, some differences were found when we replicated the experiment for 
Donor 2. Whilst in the first test the positive control had significant elevated levels of biofilm 
biomass relative to the various biomaterials tested suggesting a bacteriostatic effect of the 
preparations, in the replicate experiment with Donor 2 blood products the positive control 
showed elevated levels of biofilm biomass but showed wide variation in the 6 replicates 
such that the biomaterial effect did not reach statistical significance. Increasing the sample 
size should help to decide if the effect is real for the various PRP preparations. Moreover, 
against P. aeruginosa for donor 1 the pre-Calcium Chloride-activated form of L-PRP 
showed a greater ability in controlling biofilm formation compared to the identical un-
activated L-PRP form (p<0.01). This finding was not confirmed for donor 2.  
Looking at the growth of P. aeruginosa in its planktonic state we confirmed findings 
previously reported by other others [97, 113, 114] in that PRP and PPP preparations 
significantly reduced bacterial growth. We found comparable results against A. baumannii 
and these are important data as few studies have tested the antimicrobial properties of blood-
derived biomaterials against this multi-drug resistant, biofilm-forming pathogen [73, 142] 




The results reported here support the previous findings that the antimicrobial effect of PRP 
is independent of platelet concentration [91, 93, 95], at least for these Gram negative 
bacteria strains Complement itself has been suggested to be one of the major contributors to 
the antimicrobial effect of PRP preparations [96] and Complement will be present in both 
our PRP and PPP preparations and future studies should perhaps measure its concentration 
in each preparation. Some authors have even suggested that the plasma Complement rather 
than platelets or leucocytes contributes to the antibacterial effect [95, 97]. This could explain 
the failure to inhibit bacterial growth when only isolated neutrophils were included in the 
preparation, with complement and microbicidal peptides and proteins that are particularly 
abundant in PRP preparations then absent. Another possible explanation could also be that 
the preparations including only isolated neutrophils were too dilute, not reaching an 
effective concentration of neutrophils.  
According to these results it could be advocated that with the topical use of whole blood 
similar antimicrobial effects could be obtained. The mechanisms explaining the 
antimicrobial properties of blood products are not fully understood and still under debate  
[84]. It is well established  though, that platelets need activation in order to release their 
antimicrobial polypeptides [66]and also even when only PPP is used, it is relevant to specify 
that during centrifugation active substances are released[85]. In fact, as suggested by 
Cieslik-Bielecka et al.[84], the PPP name is not entirely accurate, as plasma is the part of 
blood with all of its clotting mechanisms intact. The authors suggest instead the term “cell-
poor serum” (CPS), fluid part of blood without platelets and clotting factors, but with the 





Looking at the growth of S. aureus we did not show bacteria growth control by the 
preparations that did not include leucocytes (PRP and PPP). These data are in disagreement 
with previous reports [91, 92]. The only preparation that showed the ability to control 
MSSA_F77 growth was the L-PRP preparation. Interestingly, the white blood count (WBC) 
and the neutrophil value included in L-PRP preparation, significantly affected the trajectory 
of bacterial growth inhibition. The fitted model suggested that a higher WBC and neutrophil 
value resulted in a greater dip in absorbance by 3.5 hours for the neutrophils and by 4 hours 
for WBC. Platelet, monocyte or lymphocyte numbers did not affect the bacteria growth.  
Even with minor variation in timing for different bacteria strains, our literature review 
showed that 4 hours is the optimal time of incubation when the maximum decrease of 
bacteria is achieved by the PRP biomaterials. All studies agreed that the preparations are 
bacteriostatic, resulting in regrowth, but recognise that PRP preparations are a helpful 
addition more likely to be used in a clinical setting for prophylaxis rather than 
therapeutically for the treatment of established infection. Some authors suggest using 
formulations containing leucocytes and platelets in combination during surgical debridement 
to reduce both the bacterial load and stimulate healing [86, 110, 143, 144]. 
Limtations of the study  
The main limitations of the study are the in vitro conditions of the experiments and the small 
size sample.  
The preparations used in the experiments are similar to the conditions used in previous 
published study, where PRP products are diluted in Muller-Hinton broth. It is relevant to 
remind that in clinical setting PRP products are used alone and not diluted in broth. 




not mimic the dynamic condition of an in vivo setting where the antimicrobial properties of 
each individual components of the biomaterial may be increased, prolonged or even reduced 
by the complex interaction of cellular signals, and dynamic fluid exchange.  
The study is limited to the use of samples from 8 healthy volunteers to test the microbicidal 
properties of the biomaterials against planktonic bacteria and only bloods from 2 donors to 
test the capability of the blood product to prevent biofilm formation.  Some difference in 
results have been detected in between donors in our experiments. For instance, we noticed 
some strange behaviour in the PRP measurements for donor 3 when tested against P. 
Aeruginosa, but when re-run the analysis removing donor 3 data, we obtained a similar 
result. It is paramount to mention that the donor’s variability may exist.  
The only preparation that showed the ability to control MSSA_F77 growth was the L-PRP 
preparation and we found that white blood count and the neutrophil value included in L-PRP 
preparation significantly affected the trajectory of bacterial growth inhibition, whilst 
platelet, monocyte or lymphocyte numbers did not affect the bacteria growth. Many of the 
similar patterns in the preceding analyses are likely to be due to the limited covariate data 
incorporated into the model.  We only used biomarkers measured at a single time point on 
each of the eight donors.  Hence, the model fit is likely to be very sensitive to those specific 
values.  A larger sample over a considerably larger number of donors would allow for much 
better estimation of the effect on absorbance of these biomarkers.  
The limited number of samples and donors used to test the ability of the preparations to 
prevent biofilm formation need to be strongly addressed. To test the capability to prevent 
biofilm, we used the experimental model previously described by Baugh et al. [138] and 




mimics biofilm formation in the in vivo conditions.  It would be interesting to conduct 
experiments testing the antimicrobial properities of the blood products in a preformed 
biofilm either usinga Cristal Violet assay as described by Halstead et al [105]  or mimicking 
the biofilm mode of growth alginate biofilm bactericidal assay as described by Thomsen et 
al. [86]. 
The study could be extended and replicated to confirm the findings by: 
- Testing the ability to control MSSA_F77 growth using a PRP product with a higher 
concentration of platelets (double-step method) 
- Measuring the release of different growth factors, complements and antibodies levels  
- Evaluating the contribution of leucocytes in the L-PRP preparation by measuring 
myeloperoxidase (MPO) activity and MPO release, and investigate the activity and 
capability of chemotaxis, phagocytic activity and respiratory burst of the neutrophils 
(chemiluminescence assay) included in L-PRP preparation.  
- Increasing the sample size, particularly to assess the antimicrobial property of the 
biomaterial to prevent biofilm formation 
 
Conclusion  
Blood-derived products showed different antimicrobial properties according to the bacterial 
target and the cellular composition of the product tested.  
Whilst PRP products showed significant control of Gram negative bacteria in both their 
planktonic and biofilm growth, only the preparation including leucocytes seems to exert 




This in vitro study provides preliminary evidence that blood-derived products can inhibit 
growth of key burn wound pathogens, both in their planktonic and biofilm forms.  
Taking all these findings together we suggest that the biomaterials can have a clinical 
benefit in all the circumstances where the promotion of wound healing is desired and PRP 
products can contribute to a substantial infection prophylaxis.  These preliminary results 
should be further explored: additional research should investigate the antimicrobial ability of 
these bioproducts compared to antibiotics, study the behaviour of the products against a 













1. Anitua, E., M. Sánchez, and G. Orive, Potential of endogenous regenerative 
technology for in situ regenerative medicine. Advanced Drug Delivery Reviews, 
2010. 62(7–8): p. 741-752. 
2. Posnett, J. and P.J. Franks, The burden of chronic wounds in the UK. Nurs Times, 
2008. 104(3): p. 44-5. 
3. Rawlins, J.M., et al., Epidemiology and outcome analysis of 208 children with burns 
attending an emergency department. Pediatr Emerg Care, 2007. 23(5): p. 289-93. 
4. Robson, M.C., Wound infection: a failure of wound healing caused by an imbalance 
of bacteria. Surgical Clinics of North America, 1997. 77(3): p. 637-650. 
5. Guo, S. and L.A. DiPietro, Factors affecting wound healing. Journal of dental 
research, 2010. 89(3): p. 219-229. 
6. Organization, W.H., Antimicrobial resistance: global report on surveillance. 2014: 
World Health Organization. 
7. Hancock, R.E., Peptide antibiotics. Lancet, 1997. 349(9049): p. 418-22. 
8. Davis, V.L., et al., Platelet-rich preparations to improve healing. Part II: platelet 
activation and enrichment, leukocyte inclusion, and other selection criteria. J Oral 
Implantol, 2014. 40(4): p. 511-21. 
9. Martínez‐Zapata, M.J., et al., Efficacy and safety of the use of autologous plasma 
rich in platelets for tissue regeneration: a systematic review. Transfusion, 2009. 
49(1): p. 44-56. 
10. Anitua, E., et al., Autologous platelets as a source of proteins for healing and tissue 
regeneration. THROMBOSIS AND HAEMOSTASIS-STUTTGART-, 2004. 91(1): p. 4-15. 
11. Marx, R.E., Platelet-rich plasma: evidence to support its use. Journal of oral and 
maxillofacial surgery, 2004. 62(4): p. 489-496. 
12. Dhurat, R. and M. Sukesh, Principles and Methods of Preparation of Platelet-Rich 
Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg, 2014. 7(4): p. 189-
97. 
13. Everts, P.A., et al., What do we use: platelet-rich plasma or platelet-leukocyte gel? J 
Biomed Mater Res A, 2008. 85(4): p. 1135-6. 
14. Martinez-Zapata, M.J., et al., Autologous platelet-rich plasma for treating chronic 
wounds. Cochrane Database Syst Rev, 2012. 10: p. Cd006899. 
15. Dohan Ehrenfest, D.M., L. Rasmusson, and T. Albrektsson, Classification of platelet 
concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich 
fibrin (L-PRF). Trends Biotechnol, 2009. 27(3): p. 158-67. 
16. Mishra, A., et al., Sports medicine applications of platelet rich plasma. Curr Pharm 
Biotechnol, 2012. 13(7): p. 1185-95. 
17. Alsousou, J., et al., The biology of platelet-rich plasma and its application in trauma 
and orthopaedic surgery A REVIEW OF THE LITERATURE. Journal of Bone & Joint 




18. Anitua, E., et al., Platelet-rich plasma: preparation and formulation. Operative 
Techniques in Orthopaedics, 2012. 22(1): p. 25-32. 
19. Cattaneo, M., et al., Recommendations for the standardization of light transmission 
aggregometry: a consensus of the working party from the platelet physiology 
subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis, 2013. 11(6): p. 
1183-1189. 
20. Harrison, P., et al., Guidelines for the laboratory investigation of heritable disorders 
of platelet function. British journal of haematology, 2011. 155(1): p. 30-44. 
21. Dohan Ehrenfest, D.M., et al., In search of a consensus terminology in the field of 
platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin 
(PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol, 2012. 13(7): 
p. 1131-7. 
22. Marlovits, S., et al., A new simplified technique for producing platelet-rich plasma: a 
short technical note. European Spine Journal, 2004. 13(1): p. S102-S106. 
23. Harrison, S., et al., Platelet activation by collagen provides sustained release of 
anabolic cytokines. The American journal of sports medicine, 2011. 39(4): p. 729-
734. 
24. Fufa, D., et al., Activation of platelet-rich plasma using soluble type I collagen. 
Journal of Oral and Maxillofacial Surgery, 2008. 66(4): p. 684-690. 
25. Miron, R.J., et al., Injectable platelet rich fibrin (i-PRF): opportunities in regenerative 
dentistry? Clin Oral Investig, 2017. 
26. Landesberg, R., M. Moses, and M. Karpatkin, Risks of using platelet rich plasma gel. 
Journal of Oral and Maxillofacial Surgery, 1998. 56(9): p. 1116-1117. 
27. Cmolik, B., et al., Redo cardiac surgery: late bleeding complications from topical 
thrombin-induced factor V deficiency. The Journal of thoracic and cardiovascular 
surgery, 1993. 105(2): p. 222-7; discussion 227-8. 
28. Man, D., H. Plosker, and J.E. Winland-Brown, The use of autologous platelet-rich 
plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic 
surgery. Plastic and reconstructive surgery, 2001. 107(1): p. 229-37; discussion 238-
9. 
29. Altmeyer, P., et al., Wound healing and skin physiology. 2012: Springer Science & 
Business Media. 
30. Proksch, E., J.M. Brandner, and J.M. Jensen, The skin: an indispensable barrier. 
Experimental dermatology, 2008. 17(12): p. 1063-1072. 
31. Bikle, D.D., et al., 1, 25-Dihydroxyvitamin D3 production by human keratinocytes. 
Kinetics and regulation. Journal of Clinical Investigation, 1986. 78(2): p. 557. 
32. Bullard, K.M., M.T. Longaker, and H.P. Lorenz, Fetal wound healing: current biology. 
World journal of surgery, 2003. 27(1): p. 54-61. 
33. Martin, P., Wound healing--aiming for perfect skin regeneration. Science, 1997. 
276(5309): p. 75-81. 
34. Li, J., J. Chen, and R. Kirsner, Pathophysiology of acute wound healing. Clin 
Dermatol, 2007. 25(1): p. 9-18. 
35. YAREDHEROUY, P.M., et al., Autologous platelet-derived wound healing factor 
promotes angiogenesis via avß3-integrin expression in chronic wounds. 




36. Kakudo, N., et al., Proliferation-promoting effect of platelet-rich plasma on human 
adipose–derived stem cells and human dermal fibroblasts. Plastic and reconstructive 
surgery, 2008. 122(5): p. 1352-1360. 
37. Hom, D.B., B.M. Linzie, and T.C. Huang, The healing effects of autologous platelet 
gel on acute human skin wounds. Archives of facial plastic surgery, 2007. 9(3): p. 
174-183. 
38. Kazakos, K., et al., The use of autologous PRP gel as an aid in the management of 
acute trauma wounds. Injury, 2009. 40(8): p. 801-805. 
39. Frykberg, R.G., et al., Chronic wounds treated with a physiologically relevant 
concentration of platelet-rich plasma gel: a prospective case series. Ostomy/wound 
management, 2010. 56(6): p. 36. 
40. Danielsen, P., et al., Effect of topical autologous platelet-rich fibrin versus no 
intervention on epithelialization of donor sites and meshed split-thickness skin 
autografts: a randomized clinical trial. Plastic and reconstructive surgery, 2008. 
122(5): p. 1431-1440. 
41. AM Everts, P., et al., Is the use of autologous platelet-rich plasma gels in 
gynecologic, cardiac, and general, reconstructive surgery beneficial? Current 
pharmaceutical biotechnology, 2012. 13(7): p. 1163-1172. 
42. Carter, M.J., C.P. Fylling, and L.K. Parnell, Use of platelet rich plasma gel on wound 
healing: a systematic review and meta-analysis. Eplasty, 2011. 11: p. e38. 
43. Marck, R.E., E. Middelkoop, and R.S. Breederveld, Considerations on the use of 
platelet-rich plasma, specifically for burn treatment. J Burn Care Res, 2014. 35(3): p. 
219-27. 
44. Maghsoudi, H., N. Nezami, and M. Mirzajanzadeh, Enhancement of burn wounds 
healing by platelet dressing. International journal of burns and trauma, 2013. 3(2): 
p. 96. 
45. Ching, Y.H., et al., The use of growth factors and other humoral agents to accelerate 
and enhance burn wound healing. Eplasty, 2011. 11: p. e41. 
46. Danilenko, D.M., et al., Growth factors in porcine full and partial thickness burn 
repair. Differing targets and effects of keratinocyte growth factor, platelet-derived 
growth factor-BB, epidermal growth factor, and neu differentiation factor. The 
American journal of pathology, 1995. 147(5): p. 1261. 
47. Akita, S., et al., Basic fibroblast growth factor is beneficial for postoperative color 
uniformity in split‐thickness skin grafting. Wound repair and regeneration, 2010. 
18(6): p. 560-566. 
48. Akita, S., et al., Basic fibroblast growth factor accelerates and improves second‐
degree burn wound healing. Wound repair and regeneration, 2008. 16(5): p. 635-
641. 
49. Bing, M., et al., Randomized, multicenter, double‐blind, and placebo‐controlled trial 
using topical recombinant human acidic fibroblast growth factor for deep partial‐
thickness burns and skin graft donor site. Wound repair and regeneration, 2007. 
15(6): p. 795-799. 
50. Marck, R.E., et al., The application of platelet-rich plasma in the treatment of deep 
dermal burns: A randomized, double-blind, intra-patient controlled study. Wound 




51. Lupia, E., et al., Elevated thrombopoietin in plasma of burned patients without and 
with sepsis enhances platelet activation. Journal of Thrombosis and Haemostasis, 
2009. 7(6): p. 1000-1008. 
52. Warner, P., et al., Thrombocytopenia in the pediatric burn patient. Journal of Burn 
Care & Research, 2011. 32(3): p. 410-414. 
53. Marck, R.E., et al., Time course of thrombocytes in burn patients and its predictive 
value for outcome. Burns, 2013. 39(4): p. 714-722. 
54. Anitua, E., et al., Leukocyte Inclusion within a Platelet Rich Plasma-Derived Fibrin 
Scaffold Stimulates a More Pro-Inflammatory Environment and Alters Fibrin 
Properties. PLoS One, 2015. 10(3): p. e0121713. 
55. Assoian, R., et al., Transforming growth factor-beta in human platelets. 
Identification of a major storage site, purification, and characterization. Journal of 
Biological Chemistry, 1983. 258(11): p. 7155-7160. 
56. Grotendorst, G.R., et al., Stimulation of granulation tissue formation by platelet-
derived growth factor in normal and diabetic rats. Journal of Clinical Investigation, 
1985. 76(6): p. 2323. 
57. Maciel, F.B., et al., Scanning electron microscopy and microbiological evaluation of 
equine burn wound repair after platelet-rich plasma gel treatment. Burns, 2012. 
38(7): p. 1058-65. 
58. HOSGOOD, G., Wound Healing: The Role of Platelet‐Derived Growth Factor and 
Transforming Growth Factor Beta. Veterinary Surgery, 1993. 22(6): p. 490-495. 
59. Shah, M., D.M. Foreman, and M. Ferguson, Neutralisation of TGF-beta 1 and TGF-
beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces 
scarring. Journal of cell science, 1995. 108(3): p. 985-1002. 
60. Douglas, H.E., TGF-ss in wound healing: a review. J Wound Care, 2010. 19(9): p. 403-
6. 
61. Niessen, F.B., et al., Keratinocyte‐derived growth factors play a role in the formation 
of hypertrophic scars. The Journal of pathology, 2001. 194(2): p. 207-216. 
62. Berman, B., A. Maderal, and B. Raphael, Keloids and Hypertrophic Scars: 
Pathophysiology, Classification, and Treatment. Dermatol Surg, 2016. 
63. Lichtman, M.K., M. Otero-Vinas, and V. Falanga, Transforming growth factor beta 
(TGF-beta) isoforms in wound healing and fibrosis. Wound Repair Regen, 2016. 
24(2): p. 215-22. 
64. Penn, J.W., A.O. Grobbelaar, and K.J. Rolfe, The role of the TGF-beta family in wound 
healing, burns and scarring: a review. Int J Burns Trauma, 2012. 2(1): p. 18-28. 
65. Cieslik-Bielecka, A., et al., Microbicidal properties of Leukocyte- and Platelet-Rich 
Plasma/Fibrin (L-PRP/L-PRF): new perspectives. J Biol Regul Homeost Agents, 2012. 
26(2 Suppl 1): p. 43s-52s. 
66. Yeaman, M.R., Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol, 
2014. 12(6): p. 426-37. 
67. Tang, Y.Q., M.R. Yeaman, and M.E. Selsted, Antimicrobial peptides from human 
platelets. Infect Immun, 2002. 70(12): p. 6524-33. 
68. Yeaman, M.R., The role of platelets in antimicrobial host defense. Clin Infect Dis, 




69. Sadek, M.I., et al., Chemokines induced by infection of mononuclear phagocytes with 
mycobacteria and present in lung alveoli during active pulmonary tuberculosis. 
American journal of respiratory cell and molecular biology, 1998. 19(3): p. 513-521. 
70. Lopes-Pires, M.E., et al., Lipopolysaccharide treatment reduces rat platelet 
aggregation independent of intracellular reactive-oxygen species generation. 
Platelets, 2012. 23(3): p. 195-201. 
71. Youssefian, T., et al., Host defense role of platelets: engulfment of HIV 
andStaphylococcus aureus occurs in a specific subcellular compartment and is 
enhanced by platelet activation. Blood, 2002. 99(11): p. 4021-4029. 
72. Edelblute, C.M., et al., Human platelet gel supernatant inactivates opportunistic 
wound pathogens on skin. Platelets, 2015. 26(1): p. 13-6. 
73. Edelblute, C.M., et al., Donor platelet plasma components inactivate sensitive and 
multidrug resistant Acinetobacter baumannii isolates. Pathog Dis, 2015. 73(9): p. 
ftv095. 
74. Edelblute, C.M., et al., Human platelet gel supernatant inactivates opportunistic 
wound pathogens on skin. Platelets, 2015. 26(1): p. 13-16. 
75. J., L.J.B.A.T.M.P.T.G.R.H., Platelet-derived growth factors induce the expression of 
the antimicrobial peptide human beta-defensin-2 in primary keratinocytes. 
Experimental Dermatology. Conference: 42nd Annual Meeting of the 
Arbeitsgemeinschaft Dermatologische Forschung, ADF 2015 Ulm Germany. 
Conference Start: 20150305 Conference End: 20150307. Conference Publication: 
(var.pagings). 24 (3) (pp E4), 2015. Date of Publication: March 2015., 2015. 
76. Tohidnezhad, M., et al., Platelets display potent antimicrobial activity and release 
human beta-defensin 2. Platelets, 2012. 23(3): p. 217-23. 
77. Yeaman, M.R., Bacterial-platelet interactions: virulence meets host defense. Future 
Microbiol, 2010. 5(3): p. 471-506. 
78. Zielinski, T., et al., The generation of superoxide anion in blood platelets in response 
to different forms of Proteus mirabilis lipopolysaccharide: effects of staurosporin, 
wortmannin, and indomethacin. Thrombosis research, 2001. 103(2): p. 149-155. 
79. Aktan, I., B. Dunkel, and F.M. Cunningham, Equine platelets inhibit E. coli growth 
and can be activated by bacterial lipopolysaccharide and lipoteichoic acid although 
superoxide anion production does not occur and platelet activation is not associated 
with enhanced production by neutrophils. Vet Immunol Immunopathol, 2013. 
152(3-4): p. 209-17. 
80. Zalavary, S., et al., Platelets enhance Fc (gamma) receptor-mediated phagocytosis 
and respiratory burst in neutrophils: the role of purinergic modulation and actin 
polymerization. Journal of leukocyte biology, 1996. 60(1): p. 58-68. 
81. Bengtsson, T., et al., Platelets enhance neutrophil locomotion: evidence for a role of 
P-selectin. Scandinavian journal of clinical and laboratory investigation, 1999. 59(6): 
p. 439-449. 
82. Bengtsson, T., et al., Release of oxygen metabolites from chemoattractant-
stimulated neutrophils is inhibited by resting platelets: role of extracellular 
adenosine and actin polymerization. Blood, 1996. 87(10): p. 4411-4423. 
83. Bielecki, T., et al., The role of leukocytes from L-PRP/L-PRF in wound healing and 




84. Cieslik-Bielecka, A., et al., Why the platelet-rich gel has antimicrobial activity? Oral 
Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 2007. 
103(3): p. 303-305. 
85. Bielecki, T., et al., The analysis of leukocytes for CD3, CD14, CD15, CD16, CD19, 
CD45, CD56 with progenitor cells (CD34+) and platelet-derived growth factors in 
blood and platelet-leukocyte rich plasma/gel-preliminary report. Pol. J. Environ. 
Stud, 2009. 18(1A): p. 649-652. 
86. Thomsen, K., et al., The phagocytic fitness of Leucopatches may impact the healing 
of chronic wounds. Clinical & Experimental Immunology, 2016. 
87. Pillay, J., et al., In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 
days. Blood, 2010. 116(4): p. 625-627. 
88. Klebanoff, S.J., Myeloperoxidase: contribution to the microbicidal activity of intact 
leukocytes. Science, 1970. 169(3950): p. 1095-1097. 
89. Yang, L.C., et al., Antimicrobial activity of platelet-rich plasma and other plasma 
preparations against periodontal pathogens. J Periodontol, 2015. 86(2): p. 310-8. 
90. Drago, L., et al., Antimicrobial activity of pure platelet-rich plasma against 
microorganisms isolated from oral cavity. BMC Microbiol, 2013. 13: p. 47. 
91. Anitua, E., et al., Antibacterial effect of plasma rich in growth factors (PRGF(R)-
Endoret(R)) against Staphylococcus aureus and Staphylococcus epidermidis strains, 
in Clin Exp Dermatol. 2012. p. 652-7. 
92. Moojen, D.J., et al., Antimicrobial activity of platelet-leukocyte gel against 
Staphylococcus aureus. J Orthop Res, 2008. 26(3): p. 404-10. 
93. Bielecki, T.M., et al., Antibacterial effect of autologous platelet gel enriched with 
growth factors and other active substances: an in vitro study. J Bone Joint Surg Br, 
2007. 89(3): p. 417-20. 
94. Mariani, E., et al., Platelet-rich plasma affects bacterial growth in vitro. Cytotherapy, 
2014. 16(9): p. 1294-304. 
95. Drago, L., et al., Plasma components and platelet activation are essential for the 
antimicrobial properties of autologous platelet-rich plasma: an in vitro study. PLoS 
One, 2014. 9(9): p. e107813. 
96. Daha, M.R., Role of complement in innate immunity and infections. Critical 
Reviews™ in Immunology, 2010. 30(1). 
97. Burnouf, T., et al., Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich 
plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against 
wound bacteria. Transfusion, 2013. 53(1): p. 138-46. 
98. Parsek, M.R. and P.K. Singh, Bacterial biofilms: an emerging link to disease 
pathogenesis. Annual Reviews in Microbiology, 2003. 57(1): p. 677-701. 
99. Hall-Stoodley, L. and P. Stoodley, Biofilm formation and dispersal and the 
transmission of human pathogens. Trends in microbiology, 2005. 13(1): p. 7-10. 
100. Karatan, E. and P. Watnick, Signals, regulatory networks, and materials that build 
and break bacterial biofilms. Microbiology and Molecular Biology Reviews, 2009. 
73(2): p. 310-347. 
101. Hall-Stoodley, L., et al., Direct detection of bacterial biofilms on the middle-ear 




102. Costerton, J.W., Cystic fibrosis pathogenesis and the role of biofilms in persistent 
infection. Trends in microbiology, 2001. 9(2): p. 50-52. 
103. Schaudinn, C., et al., Periodontitis: an archetypical biofilm disease. The Journal of 
the American Dental Association, 2009. 140(8): p. 978-986. 
104. Coenye, T., et al., Biofilms in skin infections: Propionibacterium acnes and acne 
vulgaris. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-
Infectious Disorders), 2008. 8(3): p. 156-159. 
105. Halstead, F.D., et al., The Antibacterial Activity of Acetic Acid against Biofilm-
Producing Pathogens of Relevance to Burns Patients. PloS one, 2015. 10(9): p. 
e0136190. 
106. Bjarnsholt, T., et al., Why chronic wounds will not heal: a novel hypothesis. Wound 
repair and regeneration, 2008. 16(1): p. 2-10. 
107. James, G.A., et al., Biofilms in chronic wounds. Wound Repair and regeneration, 
2008. 16(1): p. 37-44. 
108. Rozalski, M.I., et al., Antimicrobial/anti-biofilm activity of expired blood platelets 
and their released products. Postepy Hig Med Dosw (Online), 2013. 67: p. 321-5. 
109. Atkins, D., et al., Assessing the applicability of studies when comparing medical 
interventions. 2010. 
110. Wu, X., et al., Antimicrobial properties of single-donor-derived, platelet-leukocyte 
fibrin for fistula occlusion: An in vitro study. Platelets, 2013. 24(8): p. 632-6. 
111. Intravia, J., et al., In vitro evaluation of the anti-bacterial effect of two preparations 
of platelet rich plasma compared with cefazolin and whole blood. Muscles 
Ligaments Tendons J, 2014. 4(1): p. 79-84. 
112. Cavallo, C., et al., Comparison of Platelet-Rich Plasma Formulations for Cartilage 
Healing. An in Vitro Study. Vol. 96. 2014. 423-429. 
113. Mariani, E., et al., Leukocyte presence does not increase microbicidal activity of 
Platelet-rich Plasma in vitro. BMC Microbiol, 2015. 15: p. 149. 
114. Chen, L., et al., Antibacterial effect of autologous platelet-rich gel derived from 
subjects with diabetic dermal ulcers in vitro. J Diabetes Res, 2013. 2013: p. 269527. 
115. Lopez, C., M.E. Alvarez, and J.U. Carmona, Temporal Bacteriostatic Effect and 
Growth Factor Loss in Equine Platelet Components and Plasma Cultured with 
Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: A 
Comparative In Vitro Study. 2014. 2014: p. 525826. 
116. Li, H., et al., Unique antimicrobial effects of platelet-rich plasma and its efficacy as a 
prophylaxis to prevent implant-associated spinal infection. Adv Healthc Mater, 
2013. 2(9): p. 1277-84. 
117. Lopez, C., et al., Bacteriostatic effect of equine pure platelet-rich plasma and other 
blood products against methicillin-sensitive Staphylococcus aureus. An in vitro study. 
Vet Comp Orthop Traumatol, 2014. 27(5): p. 372-8. 
118. Bayer, A.S., et al., In vitro resistance of Staphylococcus aureus to thrombin-induced 
platelet microbicidal protein is associated with alterations in cytoplasmic membrane 
fluidity. Infection and immunity, 2000. 68(6): p. 3548-3553. 
119. Cubison, T., S.A. Pape, and N. Parkhouse, Evidence for the link between healing time 
and the development of hypertrophic scars (HTS) in paediatric burns due to scald 




120. Akhundov, K., et al., Development of a cost-effective method for platelet-rich 
plasma (PRP) preparation for topical wound healing. Ann Burns Fire Disasters, 2012. 
25(4): p. 207-13. 
121. Tanaka, Y., et al., Performance evaluation of platelet counting by novel fluorescent 
dye staining in the XN-series automated hematology analyzers. J Clin Lab Anal, 
2014. 28(5): p. 341-8. 
122. Brown, T.P.L.H., et al., Survival benefit conferred by topical antimicrobial 
preparations in burn patients: a historical perspective. Journal of Trauma and Acute 
Care Surgery, 2004. 56(4): p. 863-866. 
123. Church, D., et al., Burn wound infections. Clin Microbiol Rev, 2006. 19(2): p. 403-34. 
124. David, M.Z. and R.S. Daum, Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences of an emerging 
epidemic. Clinical microbiology reviews, 2010. 23(3): p. 616-687. 
125. Perez, F., et al., Global challenge of multidrug-resistant Acinetobacter baumannii. 
Antimicrobial agents and chemotherapy, 2007. 51(10): p. 3471-3484. 
126. Peleg, A.Y., H. Seifert, and D.L. Paterson, Acinetobacter baumannii: emergence of a 
successful pathogen. Clinical microbiology reviews, 2008. 21(3): p. 538-582. 
127. Kunz, A.N. and I. Brook, Emerging resistant Gram-negative aerobic bacilli in 
hospital-acquired infections. Chemotherapy, 2010. 56(6): p. 492-500. 
128. Moore, N.M. and M.L. Flaws, Epidemiology and pathogenesis of Pseudomonas 
aeruginosa infections. Clin Lab Sci, 2011. 24(1): p. 43-6. 
129. Lister, P.D., D.J. Wolter, and N.D. Hanson, Antibacterial-resistant Pseudomonas 
aeruginosa: clinical impact and complex regulation of chromosomally encoded 
resistance mechanisms. Clinical microbiology reviews, 2009. 22(4): p. 582-610. 
130. Fazli, M., et al., Nonrandom distribution of Pseudomonas aeruginosa and 
Staphylococcus aureus in chronic wounds. Journal of clinical microbiology, 2009. 
47(12): p. 4084-4089. 
131. Rajpaul, K., Biofilm in wound care. Br J Community Nurs, 2015. Suppl Wound Care: 
p. S6, s8, s10-1. 
132. Norman, G., et al., Antibiotics and antiseptics for surgical wounds healing by 
secondary intention. Cochrane Database Syst Rev, 2016. 3: p. Cd011712. 
133. Uyesaka, N., A. Tajiri, and K. Arai, Separation of human neutrophils in self-generated 
continuous density gradients of Percoll. Jpn J Physiol, 1989. 39(4): p. 629-34. 
134. Wewers, M.D., et al., Tumor necrosis factor infusions in humans prime neutrophils 
for hypochlorous acid production. Am J Physiol, 1990. 259(4 Pt 1): p. L276-82. 
135. Ryssel, H., et al., The antimicrobial effect of acetic acid—an alternative to common 
local antiseptics? Burns, 2009. 35(5): p. 695-700. 
136. Ferraro, M.J., Performance standards for antimicrobial disk susceptibility tests. 
2000: NCCLS. 
137. Webber, M.A., et al., The global consequence of disruption of the AcrAB-TolC efflux 
pump in Salmonella enterica includes reduced expression of SPI-1 and other 
attributes required to infect the host. J Bacteriol, 2009. 191(13): p. 4276-85. 
138. Baugh, S., et al., Loss of or inhibition of all multidrug resistance efflux pumps of 
Salmonella enterica serovar Typhimurium results in impaired ability to form a 




139. Araki, J., et al., Optimized preparation method of platelet-concentrated plasma and 
noncoagulating platelet-derived factor concentrates: maximization of platelet 
concentration and removal of fibrinogen. Tissue Engineering Part C: Methods, 2011. 
18(3): p. 176-185. 
140. Gjødsbøl, K., et al., Multiple bacterial species reside in chronic wounds: a 
longitudinal study. International wound journal, 2006. 3(3): p. 225-231. 
141. Krom, B.P. and J. Oskam, Microbial biofilms and wound healing: an ecological 
hypothesis. Phlebology, 2014. 29(1 suppl): p. 168-173. 
142. Sun, S., et al., Combating Superbug Without Antibiotic on a Postamputation Wound 
in a Patient with Diabetic Foot. Int J Low Extrem Wounds, 2016. 15(1): p. 74-7. 
143. Jia, W.T., et al., The prophylactic effects of platelet-leucocyte gel in osteomyelitis: an 
experimental study in a rabbit model. J Bone Joint Surg Br, 2010. 92(2): p. 304-10. 
144. Li, G.Y., et al., Efficacy of leukocyte- and platelet-rich plasma gel (L-PRP gel) in 
treating osteomyelitis in a rabbit model. J Orthop Res, 2013. 31(6): p. 949-56. 
145. Halstead, F.D., et al., Antimicrobial dressings: Comparison of the ability of a panel of 
dressings to prevent biofilm formation by key burn wound pathogens. Burns, 2015. 







In vitro studies testing the ability of blood product to control bacteria growth 
Testing Gram positive MSSA_F77 
Laboratory of Immunology 
and Infection 
Blood products preparation  
Blood from 8 healthy donors 
- PPP 
- PRP (single- step method) 
- L-PRP 
- Isolated Neutrophils (at 
different concentration 
Neutrophil count was 
adjusted to a range of 
values:  0.5x106/ml to 
10x106/ml. 
- Neutrophils were either 
primed, using 10 ng/ml 







Laboratory T102, Institute of Microbiology and 
Infection  
Bacteria preparation MSSA_F77 
Controls preparation: MH broth, Ciprofloxacin  
 
Kirby Bauer disk diffusion 
LB agar plate coated with MSSA_F77 and PPP, PRP, L-
PRP  
 
Growth Kinetics assay 
4 replicates for each donor 
MSSA-F77 with PPP 
MSSA-F77 with PRP 
MSSA-F77 with L-PRP  
MSSA_F77 with isolated neutrophils  
MSSA_F77 with MH broth 
MSSA_F77 with Ciprofloxacin  
 
Bacteria growth after 24h  
Visual assessment of turbidity 




Testing Gram negative PS_PA01 and AB_AYE 
Laboratory of Immunology 
and Infection 
Blood products preparation  
Blood from 8 healthy donors 
- PPP 








Laboratory T102, Institute of Microbiology and 
Infection  
Bacteria preparation PS_PA01 and AB_AYE 
Controls preparation: sterile water, acetic acid, MH broth 
 
Kirby Bauer disk diffusion 
LB agar plate coated with PS_PA01 and PPP, PRP and 
L-PRP 
 
Growth Kinetics assay 
6 replicates for each donor 
PS_PA01 and AB_AYE with PPP 
PS_PA01 and AB_AYE with PRP 
AB_AYE with MH broth 
PS_PA01 with sterile water  
PS_PA01 and AB_AYE with 5% acetic acid 
 
Bacteria growth after 24h  
Visual assessment of turbidity 






In vitro studies testing the ability of blood product to prevent biofilm formation 
 
Laboratory of Immunology 
and Infection 
Blood product preparations  
Blood from 2 healthy donors 
- PPP 
- PRP (double- step 
method) 








Laboratory T102, Institute of Microbiology and 
Infection  
Bacteria preparation PS_PA01 and AB_AYE 




Cristal Violet assay  
6 replicates for each donor 
PS_PA01 with sterile water 
PS_PA01 with activated L-PRP 
PS_PA01 with no-activated L-PRP 
PS_PA01 with PRP 
PS_PA01 with PPP 
PS_PA01 with 5% acetic acid  
MH Broth  
 
AB_AYE with MH Broth  
AB_AYE with activated L-PRP 
AB_AYE with no-activated L-PRP 
AB_AYE with PRP 
AB_AYE with PPP 




Bacteria growth after 24h  
Visual assessment of turbidity of all preparations  
 
 
 
 
